Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc. et al
| Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., Mylan Pharmaceuticals, Inc., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Torrent Pharma Inc., S&B Pharma, Inc., MSN Laboratories Private Limited, Dr. Reddys Laboratories, Inc., Nostrum Laboratories Inc., Glenmark Pharmaceuticals Limited, Glenmark Pharmaceuticals Inc., USA, Breckenridge Pharmaceutical, Inc., First Time US Generics LLC, Biocon Pharma, Inc., Strides Global Pharma Private Limited, Cadila Healthcare Limited, Alkem Laboratories Ltd., Hetero USA Inc., Nostrum Pharmaceuticals, LLC, MSN Pharmaceuticals Inc., Par Pharmaceutical Inc., Strides Pharma, Inc., Prinston Pharmaceutical Inc., Heritage Pharmaceuticals Inc., Aurobindo Pharma USA, Inc., Dr. Reddys Laboratories, Ltd., Hetero Labs Limited Unit-V, Intas Pharmaceuticals Limited, Standard Chemical & Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA Inc., Sun Pharmaceutical Industries Inc., Apotex Corp., Apotex Inc., Sun Pharma Global FZE and Actavis Elizabeth LLC |
| Biocon Limited, HEC Pharm Group, HEC Pharm Co., Ltd., Ezra Ventures, LLC, HEC Pharm USA Inc., Hetero Labs Limited, Aurobindo Pharma Limited and Bionpharma Inc. |
| Novartis Pharmaceuticals Corporation |
| 1:2018cv01043 |
| July 16, 2018 |
| US District Court for the District of Delaware |
| Wilmington Office |
| New Castle |
| Kent A Jordan |
| Leonard P Stark |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 Patent Infringement |
| Defendant |
Docket Report
RSS Track this Docket
This docket was last retrieved on April 11, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
CASE NO LONGER REFERRED to Magistrate Judge Burke for the purpose of exploring ADR. Please see the Court's Standing Order No. 2022-2 dated March 14, 2022. (dlb)
|
|
Filing 818
Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Joint Status Report - re (38 in 1:18-cv-01040-LPS) Order, (55 in 1:18-cv-01038-LPS) Order,. (Silver, Daniel)
|
|
Filing 817
FINAL JUDGMENT AND ORDER OF INJUNCTION - re Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. Signed by Judge Kent A. Jordan on 1/21/21. (amf)
|
|
Filing 816
PROPOSED CONSENT JUDGMENT and Order of Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 815
ORDER - In accordance with the Court's December 10, 2020 Order (D.I. #810 ), the Clerk's Office is hereby directed to unseal the Memorandum Opinion of December 10, 2020 (D.I. #809 ). Signed by Judge Kent A. Jordan on 12/16/2020. (amf)
|
|
Filing 814
Letter to The Honorable Kent A. Jordan from Daniel M. Silver, Esq. regarding Parties' Request to Unseal Memorandum Opinion (D.I. 809) - re #810 Order,. (Silver, Daniel)
|
|
Filing 813
ORDER - Plaintiff Novartis's Motion to Extinguish Any Claim by Defendant HEC To The Preliminary Injunction Bond (D.I. #785 ) is GRANTED. Signed by Judge Kent A. Jordan on 12/15/2020. (amf)
|
|
Filing 812
MEMORANDUM OPINION. Signed by Judge Kent A. Jordan on 12/15/2020. (amf)
|
|
Filing 811
ORDER, denying D.I. #784 Motion for partial Stay of the final judgment; denying as moot D.I. #796 Motion for Leave to File. Signed by Judge Kent A. Jordan on 12/10/2020. (myr)
|
|
Filing 810
ORDER, re D.I. #809 Memorandum Opinion (UNDER SEAL). Counsel shall provide the Court with proposed redactions to that document on or before the close of business on December 21, 2020. After that time the Court will unseal the Memorandum Opinion, setting forth the rulings, with any redactions deemed appropriate by the Court. Signed by Judge Kent A. Jordan on 12/10/2020. (myr)
|
|
Filing 809
MEMORANDUM OPINION. Signed by Judge Kent A. Jordan on 12/10/2020.This order has been emailed to local counsel. (myr)
|
|
Filing 808
FINAL JUDGMENT and ORDER OF INJUNCTION re #807 Proposed Order filed by Novartis Pharmaceuticals Corporation. Signed by Judge Kent A. Jordan on 12/2/2020. (myr)
|
|
Filing 807
PROPOSED ORDER Final Judgment and Order of Injunction by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
|
|
Filing 806
FINAL JUDGMENT and ORDER OF INJUNCTION. Signed by Judge Kent A. Jordan on 11/12/2020. (nmg)
|
|
Filing 805
PROPOSED ORDER Final Judgment and Order of Injunction as to Defendants Torrent Pharmaceuticals, Ltd. and Torrent Pharma, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 804
FINAL JUDGMENT AND ORDER OF INJUNCTION. Signed by Judge Kent A. Jordan on 10/27/2020. (nmg)
|
|
Filing 803
PROPOSED CONSENT JUDGMENT and Order of Injunction by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
|
|
Filing 802
REPLY BRIEF re #796 MOTION for Leave to File a Sur-Reply In Support of Its Opposition to HEC's Motion for Partial Stay of the Final Judgment filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 801
ANSWERING BRIEF in Opposition re #796 MOTION for Leave to File a Sur-Reply In Support of Its Opposition to HEC's Motion for Partial Stay of the Final Judgment filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..Reply Brief due date per Local Rules is 10/28/2020. (Stamoulis, Stamatios)
|
|
Filing 800
FINAL JUDGMENT AND ORDER OF INJUNCTION- in favor of Novartis Pharmaceuticals Corporation against Sun Pharma Global FZE, Sun Pharmaceutical Industries Inc., Sun Pharmaceutical Industries Ltd., re #795 Proposed Consent Judgment filed by Novartis Pharmaceuticals Corporation. Signed by Judge Kent A. Jordan on 10/21/2020. (myr)
|
|
Filing 799
FINAL JUDGMENT AND ORDER OF INJUNCTION- in favor of Novartis Pharmaceuticals Corporation against Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd. re #793 Proposed Consent Judgment filed by Novartis Pharmaceuticals Corporation. Signed by Judge Kent A. Jordan on 10/21/2020. (myr)
|
|
Filing 798
NOTICE requesting Clerk to remove Michael P. Kelly as co-counsel.. (Silver, Daniel)
|
|
Filing 797
NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re #786 Notice of Appeal (Federal Circuit) filed by HEC Pharm USA Inc. and HEC Pharm Co., Ltd. USCA Case Number 21-1070. (nmg)
|
|
Filing 796
MOTION for Leave to File a Sur-Reply In Support of Its Opposition to HEC's Motion for Partial Stay of the Final Judgment - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Text of Proposed Order)(Silver, Daniel)
|
|
Filing 795
PROPOSED CONSENT JUDGMENT and Order of Injunction as to Defendants Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., and Sun Pharma Global FZE by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 794
REPLY BRIEF re #785 MOTION to Extinguish Any Claim by Defendant HEC To The Preliminary Injunction Bond filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 793
PROPOSED CONSENT JUDGMENT and Order of Injunction as to Defendants Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 792
REPLY BRIEF re #784 MOTION to Stay re #783 Judgment filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios)
|
|
Filing 791
REDACTED VERSION of #789 Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 790
REDACTED VERSION of #788 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 789
[SEALED] DECLARATION re #788 Answering Brief in Opposition, of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 1-10, #2 Certificate of Service)(Silver, Daniel)
|
|
Filing 788
[SEALED] ANSWERING BRIEF in Opposition re #784 MOTION to Stay re #783 Judgment filed by Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 10/16/2020. (Attachments: #1 Certificate of Service)(Silver, Daniel)
|
|
Filing 787
ANSWERING BRIEF in Opposition re #785 MOTION to Extinguish Any Claim by Defendant HEC To The Preliminary Injunction Bond filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..Reply Brief due date per Local Rules is 10/16/2020. (Stamoulis, Stamatios)
|
|
Filing 786
NOTICE OF APPEAL to the Federal Circuit of #770 Order, #780 Judgment,,, Order,, . Appeal filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios)
|
|
Notification regarding #786 Notice of Appeal (Federal Circuit) sent to Reporter Gaffigan (nmg)
|
|
APPEAL - Credit Card Payment of $505.00 received re #786 Notice of Appeal (Federal Circuit) filed by HEC Pharm USA Inc., HEC Pharm Co., Ltd.. ( Filing fee $505, receipt number ADEDC-3255251.) (Stamoulis, Stamatios)
|
|
Notice of Appeal and Docket Sheet to US Court of Appeals for the Federal Circuit re #786 Notice of Appeal (Federal Circuit). (nmg)
|
|
Filing 785
MOTION to Extinguish Any Claim by Defendant HEC To The Preliminary Injunction Bond - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B, #2 Text of Proposed Order)(Silver, Daniel)
|
|
Filing 784
MOTION to Stay re #783 Judgment - filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios)
|
|
Filing 783
FINAL JUDGMENT AND ORDER OF INJUNCTION - in favor of Novartis Pharmaceuticals Corporation against Alkem Laboratories Ltd. Signed by Judge Kent A. Jordan on 9/23/2020. (amf)
|
|
Filing 782
PROPOSED ORDER Proposed Final Judgment and Order of Injunction against DefendantAlkem Laboratories, Ltd. by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 781
NOTICE requesting Clerk to remove Jaimin H. Shah as co-counsel.. (Dorsney, Kenneth)
|
|
Filing 780
ORDER, FINAL JUDGMENT, AND INJUNCTION - Final judgment is entered in favor of Novartis and against HEC (1) on Novartis' claims of induced and contributory infringement under 35 U.S.C. 271(e)(2) of claims 1-6 of the '405 patent by HEC's ANDA No. 207939 and (2) on HEC's defenses and counterclaims of non-infringement and invalidity of claims 1-6 of the '405 patent, and HEC's counterclaims are dismissed with prejudice. SO ORDERED by Judge Kent A. Jordan on 9/11/2020. (*See attached Order for further details.) (amf)
|
|
Filing 779
Letter to The Honorable Kent A. Jordan, Circuit Judge from Daniel M. Silver regarding Outstanding Dispute - re #778 Proposed Order. (Silver, Daniel)
|
|
Filing 778
PROPOSED ORDER Final Judgment, and Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 777
SO ORDERED re #776 STIPULATION TO EXTEND TIME The Deadline for the parties to submit a form of Judgment to August 28, 2020 filed by Novartis Pharmaceuticals Corporation. Entered by Judge Kent A. Jordan on 8/25/2020. (kmd)
|
|
Filing 776
STIPULATION TO EXTEND TIME The Deadline for the parties to submit a form of Judgment to August 28, 2020 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 775
SO ORDERED, re #774 STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Form of Judgment to August 24, 2020 filed by Novartis Pharmaceuticals Corporation. Entered by Judge Kent A. Jordan on 8/21/2020. (kmd)
|
|
Pro Hac Vice Attorneys Shyam Shanker and Sung Bin Lee for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd)
|
|
Filing 774
STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Form of Judgment to August 24, 2020 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 773
ORDER - directing Clerk's Office to Unseal re #769 Findings of Fact & Conclusions of Law. Signed by Judge Kent A. Jordan on 8/17/20. (rwc)
|
|
Filing 772
Letter to The Honorable Kent A. Jordan from Daniel M. Silver regarding Redactions - re #769 Findings of Fact & Conclusions of Law. (Joyce, Alexandra)
|
|
Filing 771
ORDER, For the reasons set forth in the Post-Trial Findings of Act and Conclusions of Law issued in this matter today, the parties shall confer and, within ten days, submit a form of judgment order giving effect to the conclusions set forth therein. Signed by Judge Kent A. Jordan on 8/10/2020. (nmg)
|
|
Filing 770
ORDER, Whereas the Court's August 10, 2020 Post-Trial Findings of Fact and Conclusions of Law has been sealed, counsel shall provide the Court with proposed redactions to that document on or before the close of business on August 21, 2020. After that time the Court will unseal the Post-Trial Findings of Fact and Conclusions of Law, setting forth the rulings, with any redactions deemed appropriate by the Court. Signed by Judge Kent A. Jordan on 8/10/2020. (nmg)
|
|
Filing 769
FINDINGS OF FACT AND CONCLUSIONS OF LAW. Signed by Judge Kent A. Jordan on 8/10/2020. This order has been emailed to local counsel. (UNSEALED PURSUANT TO ORDER DI 773) (nmg) Modified on 8/17/2020 (rwc).
|
|
Filing 768
CONSENT JUDGMENT AND ORDER OF INJUNCTION - re Strides Global Pharma Private Limited, Strides Pharma, Inc. Signed by Judge Kent A. Jordan on 6/25/2020. (amf)
|
|
Filing 767
PROPOSED CONSENT JUDGMENT as to Defendants Strides Global Pharma Private Limited and Strides Pharma, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 766
CONSENT JUDGMENT AND ORDER OF INJUNCTION - re Emcure Pharmaceuticals and Heritage Pharmaceuticals Inc. Signed by Judge Kent A. Jordan on 5/27/2020. (amf)
|
|
Filing 765
CONSENT JUDGMENT AND ORDER OF INJUNCTION - re Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited. Signed by Judge Kent A. Jordan on 5/27/2020. (amf)
|
|
Filing 764
PROPOSED CONSENT JUDGMENT as to Defendants Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 763
PROPOSED CONSENT JUDGMENT and Order of Injunction as to Glenmark Pharmaceuticals Limited by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Pro Hac Vice Attorney Christine Ranney and Kyanna Sabanoglu for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal)
|
|
Filing 762
[SEALED] DECLARATION re #759 POST Trial Brief of Steven J. Udick by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Attachments: #1 Exhibit A and B)(Stamoulis, Stamatios)
|
|
Filing 761
NOTICE of Supplemental Proposed Conclusions of Law by HEC Pharm Co., Ltd., HEC Pharm USA Inc. (Stamoulis, Stamatios)
|
|
Filing 760
Proposed Findings of Fact by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios)
|
|
Filing 759
POST TRIAL BRIEF Responsive to Non-Infringement by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios)
|
|
Filing 758
POST TRIAL BRIEF / Novartis's Post-Trial Brief on the Validity of U.S. Pat. No. 9,187,405 by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 757
Proposed Findings of Fact by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 756
STATEMENT / Novartis's Proposed Conclusions of Law Regarding Validity of U.S. Pat. No. 9,187,405 by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
SO ORDERED, #659 MOTION for Pro Hac Vice Appearance of Attorney Christine Ranney, Kyanna Sabanoglu, Shyam Shanker, Sung Bin Lee, and Emil Nachman of Gibson, Dunn & Crutcher LLP. Ordered by Judge Kent A. Jordan on 5/5/2020. (lak)
|
|
Filing 755
CONSENT JUDGMENT. Signed by Judge Kent A. Jordan on 5/4/2020. (nmg)
|
|
Filing 754
PROPOSED CONSENT JUDGMENT and Order of Injunction as to Prinston by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 753
CONSENT JUDGMENT AND ORDER OF INJUNCTION, Judgment is entered that the accused product (the subject of Abbreviated New Drug Application No. 207945) infringes all claims of the '405 Patent asserted against Ezra in this action. Pursuant to the terms of the Settlement and License Agreement, all other claims and counterclaims by Ezra or against Ezra are dismissed WITH PREJUDICE. Novartis and Ezra each expressly waive any right to appeal or otherwise move for relief from this Consent Judgment and Order of lnjunction. *See Order for further details. Signed by Judge Kent A. Jordan on 4/30/2020. (lak)
|
|
Filing 752
CONSENT JUDGMENT and ORDER OF INJUNCTION, Judgment is entered that the accused product (the subject of Abbreviated New Drug Application No. 210252) infringes all claims of the '405 Patent asserted against Bionpharma in this action. Pursuant to the terms of the Settlement and License Agreement, all other claims and counterclaims by Bionpharma or against Bionpharma are dismissed WITH PREJUDICE. Novartis and Bionpharma each expressly waive any right to appeal or otherwise move for relief from this Consent Judgment and Order of lnjunction. *See Order for further details. Signed by Judge Kent A. Jordan on 4/30/2020.(lak)
|
|
Filing 751
PROPOSED CONSENT JUDGMENT and Order of Injunction as to Ezra by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 750
PROPOSED CONSENT JUDGMENT and Order of Injunction as to Bionpharma by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 749
NOTICE of of Supplemental Authority by HEC Pharm Co., Ltd., HEC Pharm USA Inc. (Attachments: #1 Exhibit A)(Stamoulis, Stamatios)
|
|
Filing 748
PROPOSED ORDER Corrected Proposed Conclusions of Law re #746 Proposed Order by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios)
|
|
Filing 747
STATEMENT Novartis's Proposed Conclusions of Law Regarding HEC's Infringement of U.S. Pat. No. 9,187,405 by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 746
PROPOSED ORDER Proposed Conclusions of Law by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios)
|
|
Filing 745
Proposed Findings of Fact by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 744
Proposed Findings of Fact by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Stamoulis, Stamatios)
|
|
Filing 743
POST TRIAL BRIEF on Invalidity by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Stamoulis, Stamatios)
|
|
Filing 742
POST TRIAL BRIEF on HEC's Infringement of U.S. Pat. No. 9,187,405 by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 741
Official Transcript of Bench Trial - Volume 4 held on March 5, 2020 before Judge Kent A. Jordan. Court Reporter Gail Inghram Verbano, email: GailTheCourtReporter@gmail.com. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/23/2020. Redacted Transcript Deadline set for 5/4/2020. Release of Transcript Restriction set for 7/1/2020. (bpg)
|
|
Filing 740
Official Transcript of Bench Trial - Volume 3 held on March 4, 2020 before Judge Kent A. Jordan. Court Reporter Gail Inghram Verbano, email: GailTheCourtReporter@gmail.com. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/23/2020. Redacted Transcript Deadline set for 5/4/2020. Release of Transcript Restriction set for 7/1/2020. (bpg)
|
|
Filing 739
Official Transcript of Bench Trial - Volume 2 held on March 3, 2020 before Judge Kent A. Jordan. Court Reporter Gail Inghram Verbano, email: GailTheCourtReporter@gmail.com. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/23/2020. Redacted Transcript Deadline set for 5/4/2020. Release of Transcript Restriction set for 7/1/2020. (bpg)
|
|
Filing 738
Official Transcript of Bench Trial - Volume 1 held on March 2, 2020 before Judge Kent A. Jordan. Court Reporter Gail Inghram Verbano, email: GailTheCourtReporter@gmail.com. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/23/2020. Redacted Transcript Deadline set for 5/4/2020. Release of Transcript Restriction set for 7/1/2020. (bpg)
|
|
Filing 737
NOTICE of Withdrawal of Appearance (Jennifer M. Rutter) by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd. (Rutter, Jennifer)
|
|
Filing 736
REDACTED VERSION of #734 Letter by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Phillips, John)
|
|
Minute Entry for proceedings held before Judge Kent A. Jordan - Bench Trial (day 4) completed on 3/5/2020. (Court Reporter Gail Verbano.) (amf)
|
|
Minute Entry for proceedings held before Judge Kent A. Jordan - Bench Trial day 3 held on 3/4/2020. (Court Reporter Gail Verbano.) (amf) Modified on 3/5/2020 (amf).
|
|
Filing 735
[SEALED] ORDER re #734 Letter. Signed by Judge Kent A. Jordan on 3/3/2020. (lak)
|
|
Filing 734
[SEALED] Letter to The Honorable Kent A. Jordan from John C. Phillips, Jr. regarding Status. (Attachments: #1 Attachment)(Phillips, John)
|
|
Filing 733
ORDER granting #730 MOTION for Pro Hac Vice Appearance of Attorney Steven W. Hartsell. Signed by Judge Kent A. Jordan on 3/2/2020. (nmg)
|
|
Minute Entry for proceedings held before Judge Kent A. Jordan - Bench Trial day 2 held on 3/3/2020. (Court Reporter Gail Verbano.) (lak) Modified on 3/5/2020 (amf).
|
|
Minute Entry for proceedings held before Judge Kent A. Jordan - Bench Trial day 1 held on 3/2/2020. (Court Reporter Gail Verbano.) (amf) Modified on 3/5/2020 (amf).
|
|
Filing 732
ORDER re #728 Stipulation of Dismissal filed by Novartis Pharmaceuticals Corporation. All claims, counterclaims, defenses, motions and petitions asserted in this Action by Hetero or against Hetero are dismissed with prejudice. Each Party is to bear its own costs, expenses, and attorneys' fees. *See Order for further details*. Signed by Judge Kent A. Jordan on 3/2/2020. (lak) (lak).
|
|
Filing 731
Letter to The Honorable Kent A. Jordan from Daniel M. Silver, Esq. regarding Dispute Regarding Deposition Designations for Trial. (Attachments: #1 Exhibit A)(Silver, Daniel)
|
|
CORRECTING ENTRY: D.I. #732 Order uploaded. (lak)
|
|
Filing 730
MOTION for Pro Hac Vice Appearance of Attorney Steven W. Hartsell - filed by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Stamoulis, Stamatios)
|
|
Filing 729
STIPULATION of Dismissal Between Novartis and Zydus/Cadila by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 728
STIPULATION of Dismissal Between Novartis and Hetero by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 727
Joint STIPULATION and [Proposed] Order Staying the Case as to Hetero by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Minute Entry for proceedings held before Judge Kent A. Jordan - Further teleconference with counsel, Daniel Silver and Robert Trenchard for Novartis, and Kenneth Dorsney and Howard Suh for defendant Hetero, reiterating that the parties either settle the case in its entirety or be in court on Monday for trial. Telephone Conference held on 2/28/2020. (amf)
|
|
SO ORDERED, re #726 Stipulation filed by Novartis Pharmaceuticals Corporation. Entered by Judge Kent A. Jordan on 2/28/2020. (lak)
|
|
Minute Entry for proceedings held before Judge Kent A. Jordan -Teleconference 2/28/20 at 3:25 p.m. with counsel Daniel Silver and Kenneth Dorsney regarding the Stipulation and Proposed Order Staying the case as to Hetero (D.I. #727 ). Judge told counsel that unless the case was settled in its entirety, counsel should be prepared to go to trial on Monday. He will not sign the stipulation for a stay. (No court reporter was available.) (lak) Modified on 2/28/2020 (amf).
|
|
Filing 726
STIPULATION and [Proposed] Order Regarding Use of Revised Zydus Label at Trial by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 725
EXHIBIT re #715 Proposed Pretrial Order [CORRECTED] Exhibit 6 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Letter to the Honorable Kent A. Jordan, Circuit Judge from Daniel M. Silver)(Silver, Daniel)
|
|
Minute Entry for proceedings held before Judge Kent A. Jordan - Initial Pretrial Conference held on 2/21/2020. (Court Reporter Gail Verbano.) (lak)
|
|
Filing 724
STIPULATION and [Proposed] Order Regarding Testimony on Hetero Label at Trial by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 723
REDACTED VERSION of #715 Proposed Pretrial Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 722
[SEALED] Transcript of Telephone Conference held on February 4, 2020 before Judge Kent A. Jordan. (bpg)
|
|
Filing 721
NOTICE OF SERVICE of Supplemental Expert Report of Dr. Paul M. Hoffman on Infringement of U.S. Patent No. 9,187,405 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 720
REDACTED VERSION of #707 Reply Brief by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 719
REDACTED VERSION of #706 Reply Brief, by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 718
REDACTED VERSION of #704 Reply Brief, by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 717
REDACTED VERSION of #697 Letter, by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibit A)(Haney, Megan)
|
|
Filing 716
STIPULATION of Dismissal as to Apotex Inc. and Apotex Corp. by Apotex Corp., Apotex Inc.. (Moore, David)
|
|
Filing 715
[SEALED] Proposed Pretrial Order - Joint Final by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibits 1 - 12)(Silver, Daniel)
|
|
Filing 714
NOTICE to Take Deposition of Dr. Paul Hoffman on February 17, 2020 at 9:30 a.m. at the offices of Gibson, Dunn & Crutcher LLP, 200 Park Avenue, New York, NY 10166-0193 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
|
|
Filing 713
ORDER denying Daubert motions #666 , #665 , and #664 . *See Order for further details*. Signed by Judge Kent A. Jordan on 2/7/2020. (lak)
|
|
Filing 712
REDACTED VERSION of #696 Declaration, by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 711
REDACTED VERSION of #695 Answering Brief in Opposition by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 710
REDACTED VERSION of #694 Answering Brief in Opposition by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 709
REDACTED VERSION of #693 Answering Brief in Opposition by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 708
NOTICE of [Notice of Intent to Request Redaction of Transcript of 2/4/20 teleconference which has not yet been docketed] by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc. (Phillips, John)
|
|
Minute Entry for proceedings held before Judge Kent A. Jordan - Telephone Conference held on 2/4/2020. (Court Reporter Lorraine B. Marino.) (mal)
|
|
Filing 707
[SEALED] REPLY BRIEF In Support of a Motion to Exclude Dr. Radojka Savic's Written Description Opinion filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel)
|
|
Filing 706
[SEALED] REPLY BRIEF In Support of a Motion to Exclude Dr. Robert Fujinami's Written Opinions on the EAE Experiments in the Patent filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 45, #2 Certificate of Service)(Silver, Daniel)
|
|
Filing 705
Letter to The Honorable Kent A. Jordan, Circuit Judge from Daniel M. Silver, Esq. - re #704 Reply Brief,. (Silver, Daniel)
|
|
Filing 704
[SEALED] REPLY BRIEF In Support of a Motion to Exclude Dr, Paul Hoffman's Non-Infringement Opinion filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 39-43, #2 Exhibit 44, #3 Certificate of Service)(Silver, Daniel)
|
|
Filing 703
REDACTED VERSION of #683 Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 702
REDACTED VERSION of #680 Letter by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibits A-B)(Phillips, John)
|
|
Filing 701
NOTICE OF SERVICE of Defendants' Joint Notice of Prior Art under 35 U.S.C. 282 filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Dorsney, Kenneth)
|
|
Filing 700
NOTICE to Take Deposition of Radjoka Savic on February 11, 2020 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
|
|
ORAL ORDER, A Telephone Conference is set for 2/4/2020 at 10:00 AM in Chambers before Judge Kent A. Jordan. (lak)
|
|
Filing 699
Letter to The Honorable Kent A. Jordan, Circuit Judge from Daniel M. Silver regarding Teleconference on Defendants' Motion to Strike the Supplemental Expert Reports of Dr. Fred Lublin, M.D. - re #674 MOTION to Strike Supplemental Expert Reports of Dr. Fred Lublin, M.D.. (Silver, Daniel)
|
|
Filing 698
Letter to the Honorable Kent A. Jordan from John C. Phillips, Jr. regarding Request for Teleconference on Defendants' Motion to STrike the Supplemental Expert Reports of Dr. Fred Lublin - re #674 MOTION to Strike Supplemental Expert Reports of Dr. Fred Lublin, M.D.. (Phillips, John)
|
|
Filing 697
[SEALED] Letter to the Honorable Kent A. Jordan from John C. Phillips, Jr. regarding Defendants' Reply Brief in Support of Motion to Strike Dr. Lublin's Supplemental Reports - re #674 MOTION to Strike Supplemental Expert Reports of Dr. Fred Lublin, M.D., #675 Letter, #683 Letter,. (Attachments: #1 Exhibit A)(Phillips, John)
|
|
Filing 696
[SEALED] DECLARATION re #693 Answering Brief in Opposition, #694 Answering Brief in Opposition, #695 Answering Brief in Opposition Declaration of David Abramowitz in Support of Defendants' Responses to Novartis's Daubert Motions 2-4 by Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibit 1, #2 Exhibit 2, #3 Exhibit 3, #4 Exhibit 4, #5 Exhibit 5, #6 Exhibit 6)(Phillips, John)
|
|
Filing 695
[SEALED] ANSWERING BRIEF in Opposition Defendants' Opposition to Novartis' Daubert Motion No. 4 filed by Zydus Pharmaceuticals (USA) Inc..Reply Brief due date per Local Rules is 2/3/2020. (Phillips, John)
|
|
Filing 694
[SEALED] ANSWERING BRIEF in Opposition Defendants' Opposition to Novartis' Daubert Motion 3 filed by Zydus Pharmaceuticals (USA) Inc..Reply Brief due date per Local Rules is 2/3/2020. (Phillips, John)
|
|
Filing 693
[SEALED] ANSWERING BRIEF in Opposition Defendants Opposition to Novartis's Daubert Motion 2 filed by Zydus Pharmaceuticals (USA) Inc..Reply Brief due date per Local Rules is 2/3/2020. (Phillips, John)
|
|
Filing 692
REDACTED VERSION of #671 Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 691
REDACTED VERSION of #670 Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 690
REDACTED VERSION of #669 Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 689
REDACTED VERSION of #668 Declaration,, by Novartis Pharmaceuticals Corporation. (Attachments: #1 Pt. 2 of 2)(Silver, Daniel)
|
|
Filing 688
REDACTED VERSION of #667 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 687
REDACTED VERSION of #666 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 686
REDACTED VERSION of #665 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 685
REDACTED VERSION of #664 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 684
REDACTED VERSION of #663 Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 683
[SEALED] Letter to the Honorable Kent A. Jordan from Daniel M. Silver, Esq. regarding Novartis' Opposition to Defendants' Motion to Strike the Supplemental Infringement Reports of Dr. Fred Lublin - re #675 Letter,. (Attachments: #1 Exhibits 1 - 8, #2 Certificate of Service)(Silver, Daniel)
|
|
Filing 682
REDACTED VERSION of #677 Letter,, by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibits A-E, #2 Exhibit F)(Phillips, John)
|
|
Filing 681
REDACTED VERSION of #675 Letter, by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibits A-E, #2 Exhibit F, #3 Exhibit G-H)(Phillips, John)
|
|
Minute Entry for proceedings held before Judge Kent A. Jordan - Telephone Conference held on 1/21/2020. (Court Reporter Lorraine B. Marino.) (mal)
|
|
Filing 680
[SEALED] Letter to The Honorable Kent A. Jordan from John C. Phillips, Jr. regarding discovery dispute. (Attachments: #1 Exhibit A and B)(Phillips, John)
|
|
Filing 679
[SEALED] Letter to The Honorable Kent A. Jordan from Daniel M. Silver, Esq. regarding Defendants' Use of a Reply Expert Report - re #673 Order,, Set Scheduling Order Deadlines,. (Attachments: #1 Exhibits 1 - 12, #2 Certificate of Service)(Silver, Daniel)
|
|
Filing 678
Letter to The Honorable Kent A. Jordan from Daniel M. Silver, Esq. regarding Opposition to Defendants' Motion to Strike Novartis's Daubert Motions - re #677 Letter,,. (Silver, Daniel)
|
|
Filing 677
[SEALED] Letter to the Honorable Kent A. Jordan from John C. Phillips, Jr. regarding Defendants' Letter Brief In Support of Motion to Strike Five Purported Daubert Motions - re #676 MOTION to Strike #667 Opening Brief in Support, #671 Declaration, #670 Declaration, #666 Opening Brief in Support, #665 Opening Brief in Support, #669 Declaration, #663 Opening Brief in Support, #664 Opening Brief in Support, De. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Exhibit E, #6 Exhibit F)(Phillips, John)
|
|
Filing 676
MOTION to Strike #667 Opening Brief in Support, #671 Declaration, #670 Declaration, #666 Opening Brief in Support, #665 Opening Brief in Support, #669 Declaration, #663 Opening Brief in Support, #664 Opening Brief in Support, Defendants' Motion to Strike Five Purported Daubert Motions - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Text of Proposed Order, #2 7.1.1 Certification)(Phillips, John)
|
|
Filing 675
[SEALED] Letter to the Honorable Kent A. Jordan from John C. Phillips, Jr. regarding Defendants' Letter Brief in Support of Motion to Strike the Supplemental Expert Reports of Dr. Fred Lublin, M.D. - re #674 MOTION to Strike Supplemental Expert Reports of Dr. Fred Lublin, M.D.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Exhibit E, #6 Exhibit F, #7 Exhibit G, #8 Exhibit H)(Phillips, John)
|
|
Filing 674
MOTION to Strike Supplemental Expert Reports of Dr. Fred Lublin, M.D. - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Text of Proposed Order, #2 7.1.1 Statement)(Phillips, John)
|
|
Filing 673
ORDER, A teleconference relating to a discovery dispute has been scheduled for January 21, 2020 at 2:00 p.m. with the undersigned. Counsel for Zydus shall initiate the teleconference call. The parties are further ordered to file simultaneous letters of not more than three (3) pages outlining their position by close of business on January 20, 2020. Signed by Judge Kent A. Jordan on 1/17/2020. (lak)
|
|
Filing 672
Letter to The Honorable Kent A. Jordan from John C. Phillips, Jr. regarding requesting a discovery teleconference. (Phillips, John)
|
|
Filing 671
[SEALED] DECLARATION re #663 Opening Brief in Support, Declaration of Fred D. Lublin by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel)
|
|
Filing 670
[SEALED] DECLARATION re #663 Opening Brief in Support, Declaration of Lawrence Steinman, M.D. by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel)
|
|
Filing 669
[SEALED] DECLARATION re #663 Opening Brief in Support, Declaration of Peter J. Waibel by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel)
|
|
Filing 668
[SEALED] DECLARATION re #665 Opening Brief in Support, #667 Opening Brief in Support, #666 Opening Brief in Support, #663 Opening Brief in Support, #664 Opening Brief in Support, Declaration of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibits 1-9, #2 Exhibits 10-14, #3 Exhibits 15-17, #4 Exhibits 18-27, #5 Exhibits 28-31, #6 Exhibits 32-35, #7 Exhibits 36-37, #8 Exhibit 38 - Part 1 of 2, #9 Exhibit 38 - Part 2 of 2, #10 Certificate of Service)(Silver, Daniel)
|
|
Filing 667
[SEALED] OPENING BRIEF in Support of a Motion to Exclude Certain Prior Art Opinions by Dr. Radojka Savic filed by Novartis Pharmaceuticals Corporation.Answering Brief/Response due date per Local Rules is 1/27/2020. (Attachments: #1 Text of Proposed Order, #2 Certificate of Service)(Silver, Daniel)
|
|
Filing 666
[SEALED] OPENING BRIEF in Support of a Motion to Exclude Dr. Radojka Savic's Written Description Opinion filed by Novartis Pharmaceuticals Corporation.Answering Brief/Response due date per Local Rules is 1/27/2020. (Attachments: #1 Text of Proposed Order, #2 Certificate of Service)(Silver, Daniel)
|
|
Filing 665
[SEALED] OPENING BRIEF in Support of a Motion to Exclude Dr. Robert Fujinami's Opinions On The EAE Experiment In The Patent filed by Novartis Pharmaceuticals Corporation.Answering Brief/Response due date per Local Rules is 1/27/2020. (Attachments: #1 Text of Proposed Order, #2 Certificate of Service)(Silver, Daniel)
|
|
Filing 664
[SEALED] OPENING BRIEF in Support of a Motion to Exclude Dr. Paul Hoffman's Non-Infringement Opinion filed by Novartis Pharmaceuticals Corporation.Answering Brief/Response due date per Local Rules is 1/27/2020. (Attachments: #1 Text of Proposed Order, #2 Certificate of Service)(Silver, Daniel)
|
|
Filing 663
[SEALED] OPENING BRIEF in Support of a Motion to Exclude Opinions from Drs. Hoffman and Savic Based On The Slide Document filed by Novartis Pharmaceuticals Corporation.Answering Brief/Response due date per Local Rules is 1/27/2020. (Attachments: #1 Text of Proposed Order, #2 Certificate of Service)(Silver, Daniel)
|
|
Filing 662
STIPULATION and [Proposed] Order Regarding Novartis's Request for a Permanent Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 661
ORDER, the parties' Pretrial Order to be filed and two copies delivered to chambers before the close of business on February 7, 2020; and the bench trial shall begin on March 2, 2020, starting 9:00 a.m. Signed by Judge Kent A. Jordan on 1/8/2020. (lak)
|
|
Minute Entry for proceedings held before Judge Kent A. Jordan - Telephone Conference held on 1/8/2020. (Court Reporter Gail Verbano.) (lak)
|
|
Filing 660
NOTICE OF SERVICE of Second Supplemental Expert Report of Fred D. Lublin, M.D. Regarding Infringement filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
|
|
Filing 659
MOTION for Pro Hac Vice Appearance of Attorney Christine Ranney, Kyanna Sabanoglu, Shyam Shanker, Sung Bin Lee, and Emil Nachman of Gibson, Dunn & Crutcher LLP - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certification of Christine Ranney, #2 Certification of Kyanna Sabanoglu, #3 Certification of Shyam Shanker, #4 Certification of Sung Bin Lee, #5 Certification of Emil Nachman)(Silver, Daniel)
|
|
Filing 658
ORDER Setting Teleconference: IT IS ORDERED that a teleconference in the above-captioned matter has been scheduled for January 8, 2020 at 2:30 p.m. Counsel for Plaintiff shall initiate the teleconference call. Signed by Judge Kent A. Jordan on 12/30/2019. (amf)
|
|
Filing 657
REDACTED VERSION of #653 Stipulation and Proposed Order Staying the Case as to Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., and Sun Pharma Global FZE by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 656
ORDER: DESIGNATION OF CIRCUIT JUDGE TO HOLD A DISTRICT COURT WITHIN THE CIRCUIT, designating and assigning the Honorable Kent A. Jordan of the United States Court of Appeals for the Third Circuit. Signed by Judge D. Brooks Smith, Chief Judge of the United States Court of Appeals for the Third Circuit on 12/19/2019. (rjb)
|
|
Case Reassigned to Judge Kent A. Jordan of the United States Court of Appeals for the Third Circuit. Please include the initials of the Judge (KAJ) after the case number on all documents filed. (rjb)
|
|
SO ORDERED, re #653 STIPULATION and Proposed Order Staying the Case as to Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., and Sun Pharma Global FZE filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 12/19/19. (ntl)
|
|
Filing 655
REDACTED VERSION of #652 Proposed Consent Judgment by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Pro Hac Vice Attorney August Melcher for Cadila Healthcare Limited, for Zydus Pharmaceuticals (USA) Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr)
|
|
SO ORDERED, re #654 MOTION for Pro Hac Vice Appearance of Attorney August Melcher filed by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Limited. Signed by Judge Leonard P. Stark on 12/18/19. (ntl)
|
|
Filing 654
MOTION for Pro Hac Vice Appearance of Attorney August Melcher - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Certification of August Melcher)(Haney, Megan)
|
|
Filing 653
[SEALED] STIPULATION and Proposed Order Staying the Case as to Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., and Sun Pharma Global FZE by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
SO ORDERED, re #652 Consent Judgment and Order of Injunction filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 12/16/19. (ntl)
|
|
Filing 652
[SEALED] PROPOSED CONSENT JUDGMENT and Order of Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel)
|
|
Filing 651
NOTICE OF SERVICE of Supplemental Expert Report of Fred D. Lublin, M.D. Regarding Infringement filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
|
|
Filing 650
NOTICE to Take Deposition of William J. Jusko, Ph.D. on December 9, 2019 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 649
NOTICE to Take Deposition of Fred D. Lublin, M.D. on December 13, 2019 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 648
NOTICE to Take Deposition of Lawrence Steinman, M.D. on December 17, 2019 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 647
NOTICE OF SERVICE of Supplemental Expert Report of William J. Jusko, Ph.D. on the Validity of U.S. Patent No. 9,187,405 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
|
|
Filing 646
NOTICE to Take Deposition of Paul M. Hoffman filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
|
|
Filing 645
NOTICE to Take Deposition of Robert Fujinami on December 19, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
|
|
Filing 644
NOTICE to Take Deposition of Radojka Savic on November 22, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
|
|
Filing 643
NOTICE OF SERVICE of (1) Reply Expert Report of Dr. Robert Fujinami on Secondary Considerations Related to U.S. Patent No. 9,187,405; (2) Reply Expert Report of Dr. Paul M. Hoffman on Secondary Considerations Related to U.S. Patent No. 9,187,405; and (3) Reply Declaration of Dr. Radojka Savic on Invalidity of U.S. Patent No. 9,187,405 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 642
NOTICE requesting Clerk to remove Mary Procaccio-Flowers of Wilson Sonsini Goodrich & Rosati as co-counsel. Reason for request: no longer working on the matter. (Palapura, Bindu)
|
|
Filing 641
NOTICE requesting Clerk to remove Charles A. Weiss as co-counsel.. (Dorsney, Kenneth)
|
|
Filing 640
NOTICE of Change of Law Firm Affiliation by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc. (Dorsney, Kenneth)
|
|
Filing 639
NOTICE OF SERVICE of (1) Second Expert Report of Fred D. Lublin, M.D.; (2) First Expert Report of William J Jusko, Ph.D.; and (3) First Expert Report of Lawrence Steinman, M.D. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel)
|
|
Filing 638
NOTICE OF SERVICE of Rebuttal Expert Report of Dr. Paul M. Hoffman on Infringement of U.S. Patent No. 9,187,405 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 637
Redaction of #580 Transcript. Official Transcript of Preliminary Injunction Hearing held on June 21, 2019 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone number (302) 573-6360. (bpg)
|
|
Filing 636
ORAL ORDER: In light of the stay of this case as to Mylan, IT IS HEREBY ORDERED that the following motions are DENIED WITHOUT PREJUDICE TO RENEW upon the lifting of the stay: D.I. 522, 533. ORDERED by Judge Leonard P. Stark on 9/6/19. (ntl)
|
|
SO ORDERED, re #635 STIPULATION and [Proposed] Order Staying the Case as to Dr. Reddy's. Signed by Judge Leonard P. Stark on 9/5/19. (ntl)
|
| Filing 635 STIPULATION and [Proposed] Order Staying the Case as to Dr. Reddy's by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 634 Redaction of #308 Transcript. Telephone Conference held on December 21, 2018 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. (bpg) |
| Filing 633 NOTICE requesting Clerk to remove Forrest M. McClellen as co-counsel.. (Poff, Adam) |
| Filing 632 STATEMENT re #629 Order Unsecured Bond for Preliminary Injunction Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 631 NOTICE OF SERVICE of Novartiss Amended Responses to Defendants First Set of Joint Requests for Admission (Nos. 1, 3-7) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 630 REDACTED VERSION of #627 Exhibit to a Document by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
|
Filing 629
ORDER ON PRELIMINARY INJUNCTION re #357 MOTION for Preliminary Injunction filed by Novartis Pharmaceuticals Corporation, #583 Memorandum Order. Signed by Judge Leonard P. Stark on 8/1/19. (ntl)
|
|
Filing 628
ORDER re #626 MOTION to Redact #580 Transcript, #581 Transcript filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 8/1/19. (ntl)
|
| Filing 627 [SEALED] EXHIBIT re #626 MOTION to Redact #580 Transcript,, #581 Transcript A by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 626 MOTION to Redact #580 Transcript,, #581 Transcript - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit B, #2 Text of Proposed Order)(Silver, Daniel) |
| Filing 625 PROPOSED ORDER on Preliminary Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
|
Filing 624
ORAL ORDER: Having reviewed the parties' letters (D.I. 610, 612), IT IS HEREBY ORDERED that Defendants' request that Novartis produce additional witness(es) to provide Rule 30(b)(6) testimony is GRANTED with respect to Topics 1, 6, and 14. These requests are adequately tailored to be proportional to the needs of the case, plainly seek relevant evidence (with respect to, for example, validity of the patent-in-suit), and Novartis' objections with respect to these topics are unpersuasive. However, Defendants' requests for testimony on the other disputed topics are DENIED, for reasons including that these topics are overbroad (e.g., Topics 2, 13), not proportional to the needs of the case (e.g., Topics 7-9, given that the inventors themselves have been deposed, one no longer works for Novartis, and the other lives outside the U.S.; Topics 10-12, given that Defendants may be able to discern the answers in documents produced and have deposed individuals personally knowledgeable about these topics), and/or more properly the subject of expert testimony (Topic 15), particularly given the stage of this litigation. The Court further orders that, prior to any additional 30(b)(6) deposition(s), the parties meet and confer and make reasonable efforts to limit or eliminate the need for such deposition(s) by determining if any testimony already provided pursuant to Rule 30(b)(1) should be designated as binding, corporate testimony under Rule 30(b)(6). ORDERED by Judge Leonard P. Stark on 7/25/19. (ntl)
|
|
SO ORDERED, re #618 Stipulation and Order to Extend Time filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 7/24/19. (ntl)
|
| Filing 623 NOTICE OF SERVICE of Declaration of Dr. Radojka Savic on Invalidity of U.S. Patent No. 9,187,405 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 622 REDACTED VERSION of #613 Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 621 REDACTED VERSION of #612 Letter by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 620 NOTICE OF SERVICE of Opening Expert Report of Dr. Paul M. Hoffman On Invalidity of U.S. Patent No. 9,187,405 and Opening Expert Report of Dr. Robert Fujinami on EAE and U.S. Patent No. 9,187,405 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 619 NOTICE OF SERVICE of (1) First Expert Report of Fred D. Lublin, M.D., and (2) Expert Report of Christopher A. Vellturo, Ph.D. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 618 STIPULATION Extend Deadline for Parties to Submit Redaction Requests Regarding the June 21, 2019 Preliminary Injunction Hearing to July 29, 2019 by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 617 REDACTED VERSION of #610 Letter, by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Attachments: #1 Declaration, #2 Exhibit A-6)(Stamoulis, Stamatios) |
|
SO ORDERED, re #616 STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit Redaction Request regarding June 21, 2019 Preliminary Injunction Hearing to July 22, 2019 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 7/17/19. (ntl)
|
| Filing 616 STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit Redaction Request regarding June 21, 2019 Preliminary Injunction Hearing to July 22, 2019 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
|
Filing 615
ORAL ORDER: For the reasons stated in the Court's Memorandum Opinion (D.I. 575 at 6-7 n.4), IT IS HEREBY ORDERED that Mylan's motion to seal (D.I. 333) is DENIED. ORDERED by Judge Leonard P. Stark on 7/15/19. (ntl)
|
| Filing 614 REDACTED VERSION of #608 Stipulation by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 613 [SEALED] DECLARATION re #612 Letter of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 1-5, #2 Certificate of Service)(Silver, Daniel) |
| Filing 612 [SEALED] Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Responsive Letter - re #610 Letter,. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
|
SO ORDERED, re #608 Stipulation and Order Staying Claims against Mylan filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 7/12/19. (ntl)
|
|
SO ORDERED, re #607 Stipulation and Order Staying the Case as to Aurobindo filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 7/12/19. (ntl)
|
| Filing 611 Letter to Honorable Leonard P. Stark from Daniel M. Silver regarding Discovery Issues - re 606 Order,,. (Joyce, Alexandra) |
| Filing 610 [SEALED] Letter to The Honorable Leonard P. Stark from Defendants regarding Discovery Dispute - re 606 Order,,. (Attachments: #1 Declaration of Mieke K. Malmberg, #2 Exhibit A, #3 Exhibit B, #4 Exhbit C, #5 Exhibit D)(Weinblatt, Richard) |
| Filing 609 REDACTED VERSION of #604 Stipulation by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 608 [SEALED] STIPULATION and Proposed Order Staying Claims Against Mylan by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 607 [SEALED] STIPULATION and Proposed Order Staying the Case as to Aurobindo by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 7/9/2019 (ntl). |
|
Filing 606
ORAL ORDER: Having reviewed the parties' joint status report (D.I. 588), IT IS HEREBY ORDERED that: (i) the parties shall submit an agreed-upon form of order for the Court to sign, granting the preliminary injunction motion and imposing an obligation that Plaintiff post a $50 million unsecured bond; and (ii) the parties shall file letters relating to their pending disputes regarding 30(b)(6) deposition notices on July 10 and 12 (the Court will determine if it needs a discovery teleconference after reviewing the letters). ORDERED by Judge Leonard P. Stark on 7/9/19. (ntl)
|
| Pro Hac Vice Attorney Alan H. Pollack,Louis H. Weinstein for Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lak) |
|
SO ORDERED, re #604 Stipulation and Order Staying the Case as to Torrent filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 7/8/19. (ntl)
|
| Filing 605 NOTICE OF SERVICE of Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s Objections and Responses to Plaintiff's First Set of Requests for Admission [Nos. 1-9] filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Filing 604 [SEALED] STIPULATION Staying the Case as to Torrent by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 603 NOTICE OF SERVICE of Amended Privilege Log filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 602 REDACTED VERSION of #286 Letter by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 601 REDACTED VERSION of #225 Letter by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 600 REDACTED VERSION of #220 Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 599 REDACTED VERSION of #163 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 598 REDACTED VERSION of #333 MOTION to Seal Limited Sections of Transcript by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Proposed Order, #2 Exhibit A, #3 Exhibit B)(Ewing, Alexandra) |
| Filing 597 REDACTED VERSION of #296 Letter to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding Regarding Mylan Pharmaceuticals, Inc.'s Response to Novartis Concerning Redaction Dispute by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Filing 596 REDACTED VERSION of #224 Letter to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding response to Novartis's letter of October 25, 2018 by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Filing 595 REDACTED VERSION of #219 Letter, to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding supplemental letter brief by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Filing 594 REDACTED VERSION of #207 Declaration of Brandon M. White by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 1-2)(Ewing, Alexandra) |
| Filing 593 REDACTED VERSION of #206 Reply Brief in Support of Mylan Pharmaceuticals Inc.'s Motion to Dismiss for Improper Venue by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Filing 592 REDACTED VERSION of #120 Declaration of Keith Meckstroth by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 1)(Ewing, Alexandra) |
| Filing 591 REDACTED VERSION of #119 Opening Brief in Support Of Mylan Pharmaceuticals Inc.'s Motion To Dismiss For Improper Venue by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
|
SO ORDERED, re #584 STIPULATION TO EXTEND TIME to file public copies of documents pursuant to Court's Memorandum Order (DI. 575) to July 2, 2019 filed by Mylan Pharmaceuticals, Inc.; #582 CONSENT JUDGMENT and Order of Injunction. Signed by Judge Leonard P. Stark on 7/1/19. (ntl)
|
| Filing 590 REDACTED VERSION of #582 Proposed Consent Judgment by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 589 NOTICE OF SERVICE of Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s Privilege Log filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Filing 588 Joint STATUS REPORT by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 587 NOTICE OF SERVICE of Responses to Plaintiffs First Set of Requests for Admission Nos. 1-9 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 586 NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's First Set of Requests for Admission filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 585 NOTICE OF SERVICE of Hetero's responses to Plaintiff's First Set of Requests for Admission to Hetero (Nos. 1-9) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Dorsney, Kenneth) |
| Filing 584 STIPULATION TO EXTEND TIME to file public copies of documents pursuant to Court's Memorandum Order (DI. 575) to July 2, 2019 - filed by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
|
Filing 583
MEMORANDUM ORDER re #357 MOTION for Preliminary Injunction filed by Novartis Pharmaceuticals Corporation is GRANTED. Signed by Judge Leonard P. Stark on 6/24/19. (ntl)
|
| Filing 582 [SEALED] PROPOSED CONSENT JUDGMENT and Order of Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 581 [SEALED] Official Transcript of Preliminary Injunction Hearing held on June 21, 2019 before Chief Judge Leonard P. Stark. (bpg) |
| Filing 580 Official Transcript of Preliminary Injunction Hearing held on June 21, 2019 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone number (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 7/15/2019. Redacted Transcript Deadline set for 7/25/2019. Release of Transcript Restriction set for 9/23/2019. (bpg) |
| Filing 579 [SEALED] NOTICE of Lodging of Deposition Transcript of Cristian Schnell by HEC Pharm Co., Ltd., HEC Pharm USA Inc. (Stamoulis, Stamatios) |
|
SO ORDERED, re #577 STIPULATION TO EXTEND TIME Various Deadlines to Various Dates filed by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Limited. Signed by Judge Leonard P. Stark on 6/20/19. (ntl)
|
| Filing 578 REDACTED VERSION of #574 Notice (Other) by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 577 STIPULATION TO EXTEND TIME Various Deadlines to Various Dates - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
| Filing 576 NOTICE of Appearance by Jennifer M. Rutter on behalf of Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. (Rutter, Jennifer) |
|
Filing 575
MEMORANDUM ORDER re #118 MOTION to Dismiss for Improper Venue filed by Mylan Pharmaceuticals, Inc. is GRANTED and Plaintiff's request for discovery and to file an amended complaint is DENIED. Signed by Judge Leonard P. Stark on 6/17/19. (ntl)
|
| Filing 574 [SEALED] NOTICE of Lodging by Novartis Pharmaceuticals Corporation (Attachments: #1 Certificate of Service)(Silver, Daniel) |
|
SO ORDERED, re #567 Stipulation and Order to Extend Time filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 6/13/19. (ntl)
|
| Filing 573 Letter to the Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Defendants' Allocation For the Preliminary Injunction Hearing - re 332 Order,,,,,, Set Hearings,,,,,. (Phillips, John) |
| Filing 572 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding June 21, 2019 Preliminary Injunction Hearing - re 332 Order,,,,,, Set Hearings,,,,,. (Attachments: #1 [Proposed] Order Regarding June 21, 2019 Preliminary Injunction)(Silver, Daniel) |
| Filing 571 REPLY BRIEF re #522 MOTION to Dismiss for Failure to State a Claim Under Rule 12(b)(6) filed by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Filing 570 REDACTED VERSION of #565 Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 569 REDACTED VERSION of #564 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 568 REDACTED VERSION of #562 Proposed Consent Judgment by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
|
SO ORDERED, re #562 [SEALED] PROPOSED CONSENT JUDGMENT and Order of Injunction filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 6/11/19. (ntl)
|
| Filing 567 STIPULATION and [Proposed] Order to Extend the Time the deadline for the parties to submit letters to the Court regarding the June 21, 2019 preliminary injunction hearing re 332 Order,,,,,, Set Hearings,,,,, to June 12, 2019 by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 566 NOTICE OF SERVICE of Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Privilege Log filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Filing 565 [SEALED] DECLARATION re #564 Answering Brief in Opposition, Declaration of Robert W. Trenchard in Support by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibits 1-4, #2 Certificate of Service)(Silver, Daniel) |
| Filing 564 [SEALED] ANSWERING BRIEF in Opposition re #522 MOTION to Dismiss for Failure to State a Claim filed by Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 6/12/2019. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
|
Filing 563
ORDER re #561 Memorandum Opinion regarding claim construction. Signed by Judge Leonard P. Stark on 6/5/19. (ntl)
|
| Filing 562 [SEALED] PROPOSED CONSENT JUDGMENT and Order of Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 561 MEMORANDUM OPINION re claim construction. Signed by Judge Leonard P. Stark on 6/5/19. (ntl) |
| Pro Hac Vice Attorney Michael R. Laing, Maria A. Stubbings for Mylan Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| Filing 560 NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s: (1) Fourth Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories to All Defendants [Nos. 1-7]; (2) Supplemental Objections and Responses to Plaintiff's Second Set of Common Interrogatories to all Defendants [No. 8]; and (3) Supplemental Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Mylan Pharmaceuticals, Inc..(Rawnsley, Jason) |
| Filing 559 NOTICE OF SERVICE of Accord Healthcare, Inc.'s Privilege Log filed by Accord Healthcare Inc..(Ormerod, Eve) |
| Filing 558 NOTICE OF SERVICE of Plaintiff's First Amended Privilege Log filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
|
SO ORDERED, re #548 STIPULATION TO EXTEND TIME the Deadline for Plaintiff to File its Opposition to Mylans Motion to Dismiss Under Rule 12(b)(6) to June 5, 2019 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 6/3/19. (ntl)
|
|
SO ORDERED, re #532 MOTION for Pro Hac Vice Appearance of Attorney Maria A. Stubbings filed by Mylan Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 6/4/19. (ntl)
|
| Filing 557 NOTICE OF SERVICE of Novartiss Responses to Defendants First Set of Joint Requests for Admission (Nos. 1-22) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 556 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Discovery Teleconference. (Silver, Daniel) |
| Filing 555 NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Privilege Log filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 554 NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s Privilege Log filed by Mylan Pharmaceuticals, Inc..(Rawnsley, Jason) |
|
SO ORDERED, re #551 Stipulation and Order filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 6/3/19. (ntl)
|
| Filing 553 NOTICE OF SERVICE of Privilege Log filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Weinblatt, Richard) |
| Filing 552 NOTICE OF SERVICE of Hetero's Privilege Log filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Dorsney, Kenneth) |
| Filing 551 STIPULATION and [Proposed] Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 550 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Responsive Letter - re #546 Letter,. (Silver, Daniel) |
| Filing 549 REPLY to Response to Motion re #513 MOTION Novartis's Motion for Submission of Supplemental Paper in Support of Its Claim Construction Answering Brief filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 548 STIPULATION TO EXTEND TIME the Deadline for Plaintiff to File its Opposition to Mylans Motion to Dismiss Under Rule 12(b)(6) to June 5, 2019 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 547 NOTICE OF SERVICE of Plaintiff's First Set of Requests for Admission to Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 546 Letter to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding Plaintiff Novartis Pharm. Corp.'s Motion to Strike Mylan Pharmaceuticals, Inc.'s Motion to Dismiss - re #534 Letter, #535 Declaration, #533 Emergency MOTION to Strike #523 Opening Brief in Support, #522 MOTION to Dismiss for Failure to State a Claim . (Cottrell, Frederick) |
| Filing 545 NOTICE to Take Deposition of Peter Waibel on June 11, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 544 NOTICE to Take Deposition of Peter Waibel on June 11, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 543 NOTICE to Take Deposition of Dr. Christopher Vellturo on June 13, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 542 NOTICE to Take Deposition of Dr. Peter Calabresi on June 7, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 541 NOTICE to Take Deposition of Arvashni Seeripat on May 30, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 540 NOTICE to Take Deposition of Arvashni Seeripat on May 30, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 539 REDACTED VERSION of #524 Declaration, of Jason Rawnsley by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 1)(Ewing, Alexandra) |
| Filing 538 NOTICE to Take Deposition of Radhika Dasari on June 11, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 537 MEMORANDUM in Opposition re #513 MOTION Novartis's Motion for Submission of Supplemental Paper in Support of Its Claim Construction Answering Brief filed by Mylan Pharmaceuticals, Inc..Reply Brief due date per Local Rules is 5/31/2019. (Cottrell, Frederick) |
| Filing 536 REDACTED VERSION of #524 Declaration, of Jason J. Rawnsley by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 1)(Ewing, Alexandra) |
| Filing 535 DECLARATION re #534 Letter, #533 Emergency MOTION to Strike #523 Opening Brief in Support, #522 MOTION to Dismiss for Failure to State a Claim Declaration of Daniel M. Silver, Esq. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 534 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esquire regarding Novartis's Emergency Motion to Stike - re #533 Emergency MOTION to Strike #523 Opening Brief in Support, #522 MOTION to Dismiss for Failure to State a Claim . (Silver, Daniel) |
| Filing 533 Emergency MOTION to Strike #523 Opening Brief in Support, #522 MOTION to Dismiss for Failure to State a Claim - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Text of Proposed Order, #2 Text of Proposed Order, #3 Rule 7.1.1 Certification)(Silver, Daniel) |
| Filing 532 MOTION for Pro Hac Vice Appearance of Attorney Maria A. Stubbings - filed by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Filing 531 NOTICE to Take Deposition of Dr. Vijay Raghavan on June 4, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 530 REDACTED VERSION of #518 Declaration, of Robert Trenchard by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 529 REDACTED VERSION of #517 Declaration of Christopher Vellturo by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 528 REDACTED VERSION of #516 Declaration of Peter Waibel by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 527 REDACTED VERSION of #515 Declaration of Fred Lublin by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 526 REDACTED VERSION of #514 Reply Brief by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 525 REQUEST for Oral Argument by Mylan Pharmaceuticals, Inc. re #522 MOTION to Dismiss for Failure to State a Claim . (Cottrell, Frederick) |
| Filing 524 [SEALED] DECLARATION re #523 Opening Brief in Support, #522 MOTION to Dismiss for Failure to State a Claim Declaration of Jason J. Rawnsley by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 1)(Cottrell, Frederick) |
| Filing 523 OPENING BRIEF in Support re #522 MOTION to Dismiss for Failure to State a Claim filed by Mylan Pharmaceuticals, Inc..Answering Brief/Response due date per Local Rules is 6/3/2019. (Cottrell, Frederick) |
| Filing 522 MOTION to Dismiss for Failure to State a Claim - filed by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Text of Proposed Order)(Cottrell, Frederick) |
| Filing 521 NOTICE OF SERVICE of Plaintiff's Privilege Log filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 520 REDACTED VERSION of #513 MOTION Novartis's Motion for Submission of Supplemental Paper in Support of Its Claim Construction Answering Brief by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 519 NOTICE OF SERVICE of Supplemental Response to Plaintiffs First Set of Common Interrogatories filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 518 [SEALED] Second DECLARATION re #514 Reply Brief of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 240-263, #2 Exhibit 264 Pt.1, #3 Exhibit 264 Pt. 2, #4 Exhibit 265-266, #5 Certificate of Service)(Silver, Daniel) |
| Filing 517 [SEALED] DECLARATION re #514 Reply Brief of Christopher A. Vellturo, Ph.D. by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
| Filing 516 [SEALED] DECLARATION re #514 Reply Brief of Peter Waibel by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
| Filing 515 [SEALED] DECLARATION re #514 Reply Brief of Fred D. Lublin, M.D. by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
| Filing 514 [SEALED] REPLY BRIEF re #357 MOTION for Preliminary Injunction filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
|
SO ORDERED, re #511 Stipulation and Order Staying Claims against Prinston filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 5/14/19. (ntl)
|
| Filing 513 [SEALED] MOTION Novartis's Motion for Submission of Supplemental Paper in Support of Its Claim Construction Answering Brief - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Text of Proposed Order, #2 Novartis Supplemental Paper on POSA Definition, #3 Exhibit A, #4 Certificate of Service)(Silver, Daniel) |
| Filing 512 NOTICE to Take Deposition of Alpesh Pathak on May 30, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 511 STIPULATION and [Proposed] Order Staying Claims Against Prinston by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Filing 510 Letter to the Honorable Leonard P. Stark from Stamatios Stamoulis regarding Requesting a Discovery Dispute Conference. (Stamoulis, Stamatios) |
| Filing 509 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Request for a Discovery Conference regarding discovery dispute related to June 21, 2019 preliminary injunction hearing. (Silver, Daniel) |
| Filing 508 NOTICE OF SERVICE of First Set of Joint Requests for Admission filed by Mylan Pharmaceuticals, Inc..(Rawnsley, Jason) |
| Filing 507 Letter to the Honorable Leonard P. Stark from Jason J. Rawnsley (#5379) regarding Mylans request for discovery dispute teleconference. (Rawnsley, Jason) |
| Filing 506 NOTICE of Appearance by Alexandra M. Joyce on behalf of Novartis Pharmaceuticals Corporation (Joyce, Alexandra) |
| CORRECTING ENTRY: Corrected transcript added to D.I. 498 per request of court reporter. (ntl) |
| Filing 505 REDACTED VERSION of #496 Declaration by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Attachments: #1 Redacted Exhibit A, #2 Redacted Exhibit B, #3 Exhibit C)(Stamoulis, Stamatios) |
| Filing 504 REDACTED VERSION of #495 Letter by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Filing 503 NOTICE to Take Deposition of Robert Schmouder on May 17, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 502 NOTICE to Take Deposition of Peter Hiestand on May 10, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 501 NOTICE to Take Deposition of Christian Schnell on May 24, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 500 REDACTED VERSION of #490 Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 499 REDACTED VERSION of #489 Letter by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 498 Official Transcript of Claim Construction Hearing held on April 23, 2019 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 5/16/2019. Redacted Transcript Deadline set for 5/28/2019. Release of Transcript Restriction set for 7/24/2019. (bpg) |
|
Filing 497
ORAL ORDER: Having reviewed the parties' letters regarding a discovery dispute (D.I. 489, 495), IT IS HEREBY ORDERED that HEC shall produce responsive, non-privileged documents in the possession of CANDA HEC-1 LLC ("CANDA HEC"), and supplement its responses to interrogatories with any information in the possession of CANDA HEC, no later than May 15, 2019. The Court finds that Novartis has met its burden to show that Defendant HEC has sufficient control (within the meaning of Rule 34) over the relevant and responsive discovery sought by Novartis, based on at least the following: HEC's rights under Section 11.09 of its agreement with CANDA HEC, CANDA HEC's responsibility for managing the instant litigation and for marketing HEC's proposed generic product (if it is launched), and CANDA HEC's right to share in proceeds that may be derived from HEC's proposed generic product. See Robert Bosch LLC v. Alberee Prod., Inc., 2017 WL 376270, at *3 (D. Del. Jan. 24, 2017) ("The Court's finding as to BLLC's control is based on, among other things, BLLC's ability to secure from BGmbH documents that BLLC appears to have viewed as helpful to BLLC's litigation position during this litigation [and that] BLLC and BGmbH are parties to a joint venture agreement [as well as the] close interactions between BLLC and BGmbH with respect to wiper blade products."). The Court is unpersuaded by HEC's contentions that this dispute constitutes an "improper and wasteful use of the Court's time and resources" or that Plaintiff's failure to seek information by means of a Rule 45 subpoena should cause the Court to make a different finding with respect to HEC's control. IT IS FURTHER ORDERED that the discovery teleconference scheduled for tomorrow is CANCELLED. ORDERED by Judge Leonard P. Stark on 4/25/19. (ntl)
|
| Filing 496 [SEALED] DECLARATION re #495 Letter of Steven J. Udick by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C)(Stamoulis, Stamatios) |
| Filing 495 [SEALED] Letter to the Honorable Leonard P. Stark from Stamatios Stamoulis regarding Responsive Discovery Dispute Letter - re 486 Order Setting Teleconference,,,,. (Stamoulis, Stamatios) |
| Filing 494 NOTICE to Take Deposition of Ivan T. Hofmann on May 1, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 493 NOTICE to Take Deposition of Paul M. Hoffman filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Minute Entry for proceedings held before Judge Leonard P. Stark - Markman Hearing held on 4/23/2019. (Court Reporter B. Gaffigan.) (ntl) |
| Filing 492 REDACTED VERSION of #482 Statement by Accord Healthcare Inc., Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Cadila Healthcare Limited, Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., HEC Pharm Co., Ltd., HEC Pharm USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Mylan Pharmaceuticals, Inc., Prinston Pharmaceutical Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibit A)(Stamoulis, Stamatios) |
| Filing 491 NOTICE OF SERVICE of Aurobindo's First Supplemental Response to Plaintiff's 30(b)(6) Deposition Notice to Aurobindo filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Filing 490 [SEALED] DECLARATION re #489 Letter of Paul Torchia by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 1-6, #2 Certificate of Service)(Silver, Daniel) |
| Filing 489 [SEALED] Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Discovery Dispute Letter - re 486 Order Setting Teleconference,,,,. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
| Filing 488 NOTICE of Appearance by Sara M. Metzler on behalf of Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd. (Metzler, Sara) |
|
Filing 487
ORAL ORDER: IT IS HEREBY ORDERED that each side will be allocated 45 minutes for argument at the Markman Hearing scheduled for April 23, 2019. ORDERED by Judge Leonard P. Stark on 4/22/19. (ntl)
|
|
Filing 486
ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter (D.I. 382), IT IS HEREBY ORDERED that a teleconference is scheduled for April 26, 2019 at 1:15 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than April 22, 2019, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than April 24, 2019, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 4/18/19. (ntl)
|
| Filing 485 DECLARATION re #484 Claim Construction Answering Brief (of Bryan D. Beel) by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 1)(Cottrell, Frederick) |
| Filing 484 CLAIM CONSTRUCTION ANSWERING BRIEF by Defendants filed by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Filing 483 [SEALED] STATEMENT / Novartis's Response to Defendants' Technology Tutorial by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
| Filing 482 [SEALED] STATEMENT re #441 Letter DEFENDANTS COMMENTS REGARDING NOVARTIS TECHNOLOGY TUTORIAL by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Attachments: #1 Exhibit A)(Stamoulis, Stamatios) |
| Filing 481 [SEALED] Second DECLARATION re #479 Claim Construction Answering Brief (Robert W. Trenchard) by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 54, #2 Exhibit 55, #3 Exhibit 56, #4 Exhibit 57, #5 Exhibit 58, #6 Certificate of Service)(Silver, Daniel) |
| Filing 480 NOTICE OF SERVICE of Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s Objections and Responses to Novartis' Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Filing 479 [SEALED] CLAIM CONSTRUCTION ANSWERING BRIEF filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
| Filing 478 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Markman Hearing. (Silver, Daniel) |
| Filing 477 REDACTED VERSION of #465 Exhibit to a Document Exhibits to Declaration of Bryan D. Beel (Volume 5 of 5) by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Filing 476 REDACTED VERSION of #464 Exhibit to a Document Exhibits to Declaration of Bryan D. Beel (Volume 4 of 5) by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Filing 475 REDACTED VERSION of #463 Exhibit to a Document Exhibits to Declaration of Bryan D. Beel (Volume 3 of 5) by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Filing 474 REDACTED VERSION of #462 Exhibit to a Document Exhibits to Declaration of Bryan D. Beel (Volume 2 of 5) by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Filing 473 REDACTED VERSION of #461 Declaration of Bryan D. Beel (Volume 1 of 5) by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 1-25, #2 Exhibit 26-50)(Cottrell, Frederick) |
| Filing 472 REDACTED VERSION of #460 Declaration of Dr. Paul M. Hoffman on Invalidity of U.S. Patent No. 9,187,405 by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Filing 471 REDACTED VERSION of #459 Declaration of Ivan T. Hofmann by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Filing 470 REDACTED VERSION of #458 Answering Brief in Opposition Defendants' Opposition to Novartis's Motion For Preliminary Injunction by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Filing 469 NOTICE to Take Deposition of Christine Walton on April 18, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 468 NOTICE of Change of Firm Affiliation - Alan H. Pollack, Louis H. Weinstein, and James P. Barabas by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. (Ormerod, Eve) |
| Filing 467 NOTICE to Take Deposition of Shreeram Aradhye on April 18, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 466 NOTICE to Take Deposition of Nicole Cornett on April 17, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 465 [SEALED] EXHIBIT re #461 Declaration Exhibits to Declaration of Bryan D. Beel (Volume 5 of 5) by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 96-104)(Cottrell, Frederick) |
| Filing 464 [SEALED] EXHIBIT re #461 Declaration Exhibits to Declaration of Bryan D. Beel (Volume 4 of 5) by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 76-95)(Cottrell, Frederick) |
| Filing 463 [SEALED] EXHIBIT re #461 Declaration Exhibits to Declaration of Bryan D. Beel (Volume 3 of 5) by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 68-75)(Cottrell, Frederick) |
| Filing 462 [SEALED] EXHIBIT re #461 Declaration Exhibits to Declaration of Bryan D. Beel (Volume 2 of 5) by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 51-67)(Cottrell, Frederick) |
| Filing 461 [SEALED] DECLARATION re #458 Answering Brief in Opposition of Bryan D. Beel (Volume 1 of 5) by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 1-25, #2 Exhibit 26-50)(Cottrell, Frederick) |
| Filing 460 [SEALED] DECLARATION re #458 Answering Brief in Opposition of Paul M. Hoffmann by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Filing 459 [SEALED] DECLARATION re #458 Answering Brief in Opposition of Ivan T. Hofmann by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Filing 458 [SEALED] ANSWERING BRIEF in Opposition re #357 MOTION for Preliminary Injunction filed by Mylan Pharmaceuticals, Inc..Reply Brief due date per Local Rules is 4/16/2019. (Cottrell, Frederick) |
| Filing 457 REDACTED VERSION of #455 Notice (Other) by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Filing 456 NOTICE OF SERVICE of Defendant Accord Healthcare, Inc.'s Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Accord Healthcare Inc..(Ormerod, Eve) |
| Filing 455 [SEALED] NOTICE of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) of Novartis Pharmaceuticals Corporation on behalf of Defendants' by Mylan Pharmaceuticals, Inc. (Ewing, Alexandra) |
| Filing 454 NOTICE to Take Deposition of Vijay Nasare on April 9, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 453 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Discovery Conference Request - re #419 Letter. (Silver, Daniel) |
| Filing 452 NOTICE OF SERVICE of Hetero's Objections and Responses to Plaintiff's 30(b)(6) Deposition Notice filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Dorsney, Kenneth) |
| Filing 451 NOTICE OF SERVICE of Aurobindo's Objections and Responses to Plaintiff's 30(b)(6) Deposition Notice to Aurobindo filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Filing 450 NOTICE to Take Deposition of Kevin Kong on March 27, 2019 at 9:30 a.m. at the offices of Kirkland & Ellis LLP, 601 Lexington Avenue, New York, NY 10022-4611 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 449 REDACTED VERSION of #430 Declaration,, by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 1-5, #2 Exhibit 6 Pt. 1, #3 Exhibit 6 Pt. 2, #4 Exhibit 7-9, #5 Exhibit 10 Pt. 1, #6 Exhibit 10 Pt. 2, #7 Exhibit 11-14, #8 Exhibit 15 Pt. 1, #9 Exhibit 15 Pt. 2, #10 Exhibit 16-19, #11 Exhibit 20, #12 Exhibit 21-27, #13 Exhibit 28-29, #14 Exhibit 30, #15 Exhibit 31-39, #16 Exhibit 40-41, #17 Exhibit 42-43, #18 Exhibit 44-51, #19 Exhibit 52-53)(Silver, Daniel) |
| Filing 448 REDACTED VERSION of #428 Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 447 REDACTED VERSION of #427 Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 446 REDACTED VERSION of #426 Claim Construction Opening Brief by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
|
SO ORDERED, re #444 Stipulation and Order Staying the Case as to Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 3/15/19. (ntl)
|
| Filing 445 NOTICE to Take Deposition of Bradley Davis on March 21, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 444 STIPULATION and Proposed Order Staying the Case as to Defendant Alkem Laboratories, Ltd. by Alkem Laboratories Ltd.. (Dorsney, Kenneth) |
| Filing 443 Letter to the Honorable Leonard P. Stark from Stamatios Stamoulis regarding Transmitting Defendants' Technology Tutorial. (Stamoulis, Stamatios) |
| Filing 442 NOTICE OF SERVICE of Plaintiff's Technology Tutorial filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 441 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Plaintiffs' Technology Tutorial. (Silver, Daniel) |
| Filing 440 NOTICE OF SERVICE of Objections and Responses to Plaintiffs Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 439 NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc.'s and Cadila Healthcare Limited's Objections and Responses to Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 438 NOTICE to Take Deposition of Fred D. Lublin, M.D. on March 15, 2019 filed by Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 437 NOTICE to Take Deposition of Lawrence Steinman, M.D. on March 26, 2019 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 436 NOTICE to Take Deposition of William J. Jusko, Ph.D. on March 22, 2019 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 435 NOTICE to Take Deposition of Arvashni Seeripat on March 14, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 434 NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Objections and Responses to Novartis' Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
|
SO ORDERED, re #431 STIPULATION TO EXTEND TIME to Submit Tutorials Describing the Technology and Matters in Issue to March 13, 2019 filed by Mylan Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 3/8/19. (ntl)
|
|
SO ORDERED, re #425 MOTION for Pro Hac Vice Appearance of Attorney James P. Barabas filed by Dr. Reddys Laboratories, Inc., Accord Healthcare Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Dr. Reddys Laboratories, Ltd. Signed by Judge Leonard P. Stark on 3/11/19. (ntl)
|
| Pro Hac Vice Attorney James P. Barabas for Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Pharma Inc., Torrent Pharmaceuticals Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lak) |
| Filing 433 NOTICE OF SERVICE of Objections and Responses to Plaintiff's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Filing 432 NOTICE OF SERVICE of (1) Plaintiffs First Objections and Responses to Defendant Mylan Pharmaceuticals Inc.s First Set of Interrogatories to Plaintiff (Nos. 1-3); and (2) Novartiss Objections and Responses to Mylan Pharmaceuticals Inc.s Document Requests 1-4 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 431 STIPULATION TO EXTEND TIME to Submit Tutorials Describing the Technology and Matters in Issue to March 13, 2019 - filed by Mylan Pharmaceuticals, Inc.. (Rawnsley, Jason) |
| Filing 430 [SEALED] DECLARATION re #426 Claim Construction Opening Brief of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibits 1 - 5, #2 Exhibit 6, Part 1, #3 Exhibit 6, Part 2, #4 Exhibits 7 - 9, #5 Exhibit 10, Part 1, #6 Exhibit 10, Part 2, #7 Exhibits 11 - 14, #8 Exhibit 15, Part 1, #9 Exhibit 15, Part 2, #10 Exhibits 16 - 19, #11 Exhibit 20, #12 Exhibits 21 - 27, #13 Exhibits 28 - 29, #14 Exhibit 30, #15 Exhibits 31 - 39, #16 Exhibits 40 - 41, #17 Exhibits 42 - 43, #18 Exhibits 44 - 51, #19 Exhibits 52 - 53, #20 Certificate of Service)(Silver, Daniel) |
| Filing 429 [SEALED] CLAIM CONSTRUCTION OPENING BRIEF [Defendants'] filed by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Filing 428 [SEALED] DECLARATION re #426 Claim Construction Opening Brief of Lawrence Steinman, M.D. by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
| Filing 427 [SEALED] DECLARATION re #426 Claim Construction Opening Brief of William J. Jusko, Ph.D. by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
| Filing 426 [SEALED] CLAIM CONSTRUCTION OPENING BRIEF filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
| Filing 425 MOTION for Pro Hac Vice Appearance of Attorney James P. Barabas - filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| Filing 424 Letter to The Honorable Leonard P. Stark from Eve H. Ormerod regarding Plaintiff's Request for Discovery Dispute Teleconference - re #419 Letter. (Ormerod, Eve) |
| Filing 423 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Response to Mylan's and Aurobindo's Letters - re #420 Letter, #421 Letter. (Silver, Daniel) |
| Filing 422 NOTICE to Take Deposition of Christopher A. Vellturo, Ph.D. on March 8, 2019 filed by Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 421 Letter to The Honorable Leonard P. Stark from Kenneth L. Dorsney regarding Discovery Dispute - re #419 Letter. (Dorsney, Kenneth) |
| Filing 420 Letter to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding Plaintiff's Request for Discovery Dispute Teleconference - re #419 Letter. (Cottrell, Frederick) |
| Filing 419 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Requesting Discovery Dispute Conference. (Silver, Daniel) |
| Pro Hac Vice Attorney Jordan H. Bekier for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ddp) |
| Filing 418 NOTICE OF SERVICE of Responses to Plaintiffs Second Set of Common Interrogatories to All Defendants [No. 8] filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 417 NOTICE OF SERVICE of Objections and Responses to Plaintiff's Second Set of Common Interrogatories to All Defendants (No. 8) filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd..(Farnan, Kelly) |
| Filing 416 NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's Second Set of Common Interrogatories to All Defendants [No. 8] filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Filing 415 NOTICE OF SERVICE of Aurobindo's Response to Plaintiff's Second Set of Common Interrogatories (No. 8) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Filing 414 NOTICE OF SERVICE of Hetero's Responses to Second Set of Common Interrogatories (No. 8) and Prinston's Responses to Second Set of Common Interrogatories (No. 8) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Filing 413 NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiff's Second Set of Common Interrogatories to All Defendants filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 412 NOTICE OF SERVICE of Defendants' Teva Pharmaceuticals USA, Inc.'s and Actavis Elizabeth LLC's Objections and Responses to Plaintiff's Second Set of Common Interrogatories to All Defendants [No. 8] filed by Actavis Elizabeth LLC, Teva Pharmaceuticals USA Inc..(Keller, Karen) |
| Filing 411 NOTICE OF SERVICE of (1) Defendant Accord Healthcare, Inc.'s Responses and Objections to Plaintiff's Second Set of Set of Common Interrogatories to All Defendants [No. 8]; (2) Defendants Dr. Reddy's Laboratories, Ltd., Dr. Reddys Laboratories, Inc.'s Responses and Objections to Plaintiff's Second Set of Set of Common Interrogatories to All Defendants [No. 8]; and (3) Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Responses and Objections to Plaintiff's Second Set of Set of Common Interrogatories to All Defendants [No. 8] filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Filing 410 NOTICE OF SERVICE of Alkem's Objections and Resposes to Plaintiff's Second Set of Common Interrogatories (No. 8) filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
|
SO ORDERED, re #409 MOTION for Pro Hac Vice Appearance of Attorney Michael R. Laing filed by Mylan Pharmaceuticals, Inc., #394 MOTION for Pro Hac Vice Appearance of Attorney Laura Corbin filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 3/4/19. (ntl)
|
| Filing 409 MOTION for Pro Hac Vice Appearance of Attorney Michael R. Laing - filed by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Filing 408 NOTICE OF SERVICE of Aurobindo's Third Supplemental Responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Filing 407 NOTICE OF SERVICE of Hetero's Document Production [HETERO.GILENYA-0063267-0070908] filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Dorsney, Kenneth) |
| Filing 406 NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Second Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories to All Defendants filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 405 REDACTED VERSION of #363 Declaration of Christopher A. Vellturo, Ph.D. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 404 REDACTED VERSION of #371 Exhibit to a Document, #367 Exhibit to a Document, #369 Exhibit to a Document, #368 Exhibit to a Document, #370 Exhibit to a Document, Exhibits 140 - 239 of Declaration of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibits 144 - 146, #2 Exhibits 147 - 152, #3 Exhibits 153 - 160, #4 Exhibits 161 - 173, #5 Exhibits 174 - 239)(Silver, Daniel) |
| Filing 403 REDACTED VERSION of #366 Exhibit to a Document, #365 Exhibit to a Document, #367 Exhibit to a Document, Exhibits 57 - 139 to the Declaration of Rober W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibits 81 - 108, #2 EXhibits 109 - 115, #3 Exhibits 116 - 139)(Silver, Daniel) |
| Filing 402 REDACTED VERSION of #364 Declaration, of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibits 1 - 17, #2 Exhibits 18 - 25, #3 Exhibits 26 - 47, #4 Exhibits 48 - 56)(Silver, Daniel) |
| Filing 401 REDACTED VERSION of #362 Declaration of Arvashni Seeripat by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 400 REDACTED VERSION of #361 Declaration of William J. Jusko, Ph.D by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 399 REDACTED VERSION of #360 Declaration of Fred D. Lublin, M.D. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 398 REDACTED VERSION of #359 Declaration of Lawrence Steinman, M.D. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 397 REDACTED VERSION of #358 Opening Brief in Support of Novartis' Motion for a Preliminary Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 396 NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Third Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories [Nos. 1-7] filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Filing 395 NOTICE OF SERVICE of Hetero's Third Amended Paragraph 3 Disclosures filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Dorsney, Kenneth) |
| Filing 394 MOTION for Pro Hac Vice Appearance of Attorney Laura Corbin - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certification for Laura Corbin)(Silver, Daniel) |
| Filing 393 NOTICE OF SERVICE of Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddys Laboratories, Ltd.'s Third Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories [Nos. 1-7] and Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Second Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories [Nos. 1-7] filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
|
SO ORDERED, re #391 MOTION for Pro Hac Vice Appearance of Attorney Jordan Bekier filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/22/19. (ntl)
|
| Filing 392 NOTICE OF SERVICE of Defendants' Supplemental Identification of Invalidity References Regarding U.S. Patent No. 9,187,405 filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Filing 391 MOTION for Pro Hac Vice Appearance of Attorney Jordan Bekier - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certification for Jordan Bekier)(Silver, Daniel) |
| Filing 390 NOTICE to Take Deposition of Seshu Akula on March 13, 2019 at 9:30 a.m. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 389 NOTICE to Take Deposition of Anuj Srivastava on March 14, 2019 at 9:30 a.m. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 388 NOTICE to Take Deposition of Elizabeth Purcell on March 14, 2019 at 9:30 a.m. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 387 NOTICE to Take Deposition of Arunesh Varma on March 13, 2019 at 9:30 a.m. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 386 NOTICE to Take Deposition of Radhika Dasari on March 15, 2019 at 9:30 a.m. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 385 NOTICE to Take Deposition of Amit Ghare on March 12, 2019 at 9:30 am filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 384 NOTICE to Take Deposition of David Mitchell on March 15, 2019 at 9:30 a.m. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 383 NOTICE to Take Deposition of Alpesh Pathak on March 12, 2019 at 9:30 am filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 382 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Discovery Teleconference Request for Novartis and HEC. (Silver, Daniel) |
| Filing 381 NOTICE OF SERVICE of Hetero's Third Amended Response to Plaintiff's First Set of Common Interrogatories filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Dorsney, Kenneth) |
| Filing 380 NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Filing 379 NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Filing 378 NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Mylan Pharmaceuticals, Inc. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Filing 377 NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Filing 376 NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to HEC Pharm Co., Ltd and HEC Pharm USA Inc. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Filing 375 NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Dr. Reddy's Laboroatries, Inc. and Dr. Reddy's Laboratories, Ltd. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Filing 374 NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Filing 373 NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Alkem Laboratories, Ltd. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Filing 372 NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Accord Healthcare Inc. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Filing 371 [SEALED] EXHIBIT re #364 Declaration, Exhibit Nos. 236 - 239 of Declaration of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit No. 237, #2 Exhibit No. 238, #3 Exhibit No. 239, #4 Certificate of Service)(Silver, Daniel) |
| Filing 370 [SEALED] EXHIBIT re #364 Declaration, Exhibit Nos. 212 - 235 to Declaration of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 216, #2 Exhibit 217 - 226, #3 Exhibit 227 - 229, #4 Exhibit 230 - 235, #5 Certificate of Service)(Silver, Daniel) |
| Filing 369 [SEALED] EXHIBIT re #364 Declaration, Exhibit No. 211 to Declaration of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 211 part 2, #2 Exhibit 211 part 3, #3 Exhibit 211 part 4)(Silver, Daniel) |
| Filing 368 [SEALED] EXHIBIT re #364 Declaration, Exhibits Nos 153 - 210 to Declaration of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhbiits 161 -173, #2 Exhibits 174 -202, #3 Exhibits 203 - 210)(Silver, Daniel) |
| Filing 367 [SEALED] EXHIBIT re #364 Declaration, Exhibits Nos 132 -152 to Declaration of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibits 134 - 139, #2 Exhibits 140 - 143, #3 Exhibits 144 - 146, #4 Exhibits 147 - 152)(Silver, Daniel) |
| Filing 366 [SEALED] EXHIBIT re #364 Declaration, Exhibits Nos 118 -131 to Declaration of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibits 123 -124, #2 Exhibits 125 - 128, #3 Exhibits 129 -130, #4 Exhibit 131)(Silver, Daniel) |
| Filing 365 [SEALED] EXHIBIT re #364 Declaration, Exhibits Nos 57 -117 to Declaration of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibits 81 - 108, #2 Exhibits 109 - 115, #3 Exhibit 116, #4 Exhibit 117, #5 Certificate of Service)(Silver, Daniel) |
| Filing 364 [SEALED] DECLARATION re #357 MOTION for Preliminary Injunction of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibits 1 -17, #2 Exhibits 18 -25, #3 Exhibits 26 - 47, #4 Exhibits 48 - 56, #5 Certificate of Service)(Silver, Daniel) |
| Filing 363 [SEALED] DECLARATION Christopher A. Vellturo, Ph.D by Novartis Pharmaceuticals Corporation. (Attachments: #1 Appendices, #2 Certificate of Service)(Silver, Daniel) |
| Filing 362 [SEALED] DECLARATION re #357 MOTION for Preliminary Injunction of Arvashni Seeripat by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
| Filing 361 [SEALED] DECLARATION re #357 MOTION for Preliminary Injunction of William J. Jusko, Ph.D by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
| Filing 360 [SEALED] DECLARATION re #357 MOTION for Preliminary Injunction of Fred D. Lublin, M.D. by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
| Filing 359 [SEALED] DECLARATION re #357 MOTION for Preliminary Injunction of Lawrence Steinman, M.D. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 358 [SEALED] OPENING BRIEF in Support re #357 MOTION for Preliminary Injunction filed by Novartis Pharmaceuticals Corporation.Answering Brief/Response due date per Local Rules is 3/5/2019. (Silver, Daniel) |
| Filing 357 MOTION for Preliminary Injunction - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Proposed Order)(Silver, Daniel) |
| Filing 356 REDACTED VERSION of #349 Letter to The Honorable Leonard P. Stark from Kenneth L. Dorsney regarding Hetero's Responsive Dispute Letter by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Dorsney, Kenneth) |
| Filing 355 NOTICE OF SERVICE of Third Supplemental Response to Plaintiffs First Set of Common Interrogatories filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
|
SO ORDERED, re #353 Stipulation and Order Staying Claims against Bionpharma Inc., #351 Stipulation and Order Staying the Case as to Ezra Ventures, LLC. Signed by Judge Leonard P. Stark on 2/14/19. (ntl)
|
| Filing 354 NOTICE OF SERVICE of Defendants' First Supplemental Consolidated Invalidity Contentions Regarding U.S. Patent No. 9,187,405 filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Filing 353 STIPULATION Staying Claims Against Bionpharma Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
|
Filing 352
ORAL ORDER: Having reviewed the parties' letters and related materials (see, e.g., D.I. 347, 349), IT IS HEREBY ORDERED that: (i) Plaintiff's request that Hetero be barred from launching at-risk pending final resolution of this matter is DENIED, as the requested relief is "extremely unwarranted" (as Hetero correctly states) and would not be a reasonable consequence for Hetero's failures with respect to document production; (ii) Hetero SHALL complete its full document production as soon as possible and no later than February 28; (iii) Plaintiffs request that Hetero pay Novartis' fees in having to bring its motion is DENIED, although Hetero should understand that if it repeats its failure to meet deadlines and repeats its failure to give Plaintiff advance notice then the Court will impose a reasonable sanction; and (iv) Hetero SHALL, no later than February 20, respond to Interrogatory No. 3 by identifying the "key people involved in the decision about whether and when to launch the ANDA product," as disclosure of these identities is consistent with the Court's prior ruling (see D.I. 308 at 38-39) - although Hetero need not "provide a complete narrative response" that discloses "specific launch plans, specific dates, or other information about the launch plans." IT IS FURTHER ORDERED that the teleconference scheduled for today to discuss these disputes is CANCELLED. ORDERED by Judge Leonard P. Stark on 2/13/19. (ntl)
|
| Filing 351 STIPULATION and Proposed Order Staying the Case as to Ezra by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| CORRECTING ENTRY: D.I. 349 placed under seal per request of counsel. (ntl) |
| Filing 350 [SEALED] CLAIM Construction Chart by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A, #2 Exhibits B - J, #3 Exhibits K - N, #4 Exhibits O - R)(Silver, Daniel) |
| Filing 349 [SEALED] Letter to The Honorable Leonard P. Stark from Kenneth L. Dorsney regarding Discovery Dispute - re #347 Letter. (Dorsney, Kenneth) Modified on 2/11/2019 (ntl). |
|
SO ORDERED, re #344 Stipulation and Order Staying Claims against Glenmark filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/7/19. (ntl)
|
| Filing 348 DECLARATION re #347 Letter of Paul Torchia by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 1-3)(Silver, Daniel) |
| Filing 347 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Discovery Dispute - re 343 Order Setting Teleconference,,,,. (Silver, Daniel) |
| Filing 346 NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s: First Set of Interrogatories to Plaintiff Novartis Pharmaceuticals Corp. (Nos. 1-3) and First Set of Requests for the Production of Documents and Things (Nos. 1-4) filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Filing 345 NOTICE OF SERVICE of Third Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) and Third Supplemental Objections and Responses to Plaintiff's First Set of Common Requests for Production (Nos. 1-30) filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
|
SO ORDERED, re #339 STIPULATION TO EXTEND TIME for Plaintiff to Respond to Mylan's Motion to Seal Limited Sections of Transcript to through and including 14 days following the Court's ruling on the pending redaction dispute between Plaintiff and Mylan filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/6/19. (ntl)
|
|
SO ORDERED, re #341 STIPULATION TO EXTEND TIME for Breckenridge to substantially complete its document production to February 15, 2019 filed by Standard Chemical & Pharmaceutical Co., Ltd., Breckenridge Pharmaceutical, Inc., #334 STIPULATION and Order Extending Discovery and Precluding Biopharma from Launching At Risk, #336 STIPULATION and Order Extending Discovery and Precluding Prinston from Launching At Risk. Signed by Judge Leonard P. Stark on 2/6/19. (ntl)
|
| Filing 344 STIPULATION and Proposed Order Staying Claims Against Glenmark by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
|
Filing 343
ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for February 13, 2019 at 11:00 a.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than February 7, 2019, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than February 8, 2019, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 2/5/19. (ntl)
|
| CORRECTING ENTRY: D.I. 344 has been deleted at the request of counsel and will be re-filed. (etg) |
| Filing 342 NOTICE OF SERVICE of Plaintiff's Objections and Responses to Defendants' Second Joint Interrogatories to Plaintiff (Nos. 14-19) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 341 STIPULATION TO EXTEND TIME for Breckenridge to substantially complete its document production to February 15, 2019 - filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd.. (Farnan, Kelly) |
| Filing 340 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esquire regarding Scheduling of a Discovery Teleconference. (Silver, Daniel) |
| Filing 339 STIPULATION TO EXTEND TIME for Plaintiff to Respond to Mylan's Motion to Seal Limited Sections of Transcript to through and including 14 days following the Court's ruling on the pending redaction dispute between Plaintiff and Mylan - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 338 NOTICE OF SERVICE of Aurobindo's Second Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Filing 337 NOTICE OF SERVICE of Plaintiff's Second Set of Common Interrogatories to All Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 336 STIPULATION and Proposed Order Extending Discovery and Precluding Prinston Pharmaceutical, Inc. from Launching at Risk by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 335 NOTICE OF SERVICE of Plaintiffs First Supplemental Objections and Responses to Defendants First Joint Interrogatories to Plaintiff (Nos. 1-13) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 334 STIPULATION TO EXTEND TIME for Biopharma to Substantially Complete its Document Production to February 15, 2019 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 333 [SEALED] MOTION to Seal Limited Sections of Transcript - filed by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Text of Proposed Order, #2 Exhibit A, #3 Exhibit B)(Ewing, Alexandra) |
|
Filing 332
ORAL ORDER: Having reviewed the parties' letter of January 17 (D.I. 324) and subsequent joint status report (D.I. 330), IT IS HEREBY ORDERED that: (1) the parties' proposed schedule leading to a preliminary injunction motion hearing (D.I. 324 at 1-2) is ADOPTED; (2) the preliminary injunction hearing will be held on June 21 beginning at 9:00 a.m.; each side will be allocated three (3) hours for its presentation; in the unlikely event more time is necessary, the Court will work with the parties to extend the time of the hearing; (3) no later than June 11, each party participating in the preliminary injunction hearing shall submit a letter advising the Court of how it intends to use its three hours (or portion thereof), including specifically identifying which witness(es), if any, it will call to testify live; and (4) with respect to discovery, the Court appreciates the parties' update, suspects that the parties have not adequately met and conferred, and in any event directs the parties to use the Court's Discovery Matters Procedures should they seek any relief - if that occurs, the Court will be inclined to grant in its entirety the position of the party or parties who have conducted themselves most reasonably. ORDERED by Judge Leonard P. Stark on 1/28/19. (ntl)
|
| Filing 331 REDACTED VERSION of #296 Letter by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Filing 330 Joint Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Interim Status Report - re #216 Scheduling Order,,. (Silver, Daniel) |
| Filing 329 NOTICE requesting Clerk to remove Sarah K. Tsou as co-counsel.. (Hoeschen, Nathan) |
| Filing 328 NOTICE OF SERVICE of (1) Defendant Mylan Pharmaceuticals Inc.'s Second Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) and (2) Defendant Mylan Pharmaceuticals Inc.'s Second Supplemental Objections and Responses to Plaintiff's First Set of Common Requests for Production (Nos. 1-30) filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Filing 327 NOTICE of Change of Address by Stamatios Stamoulis (Stamoulis, Stamatios) |
| Filing 326 NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Helathcare Limited's First Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories to All Defendants filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 325 NOTICE OF SERVICE of (1) Aurobindo's Supplemental Paragraph 3 Disclosures; (2) Aurobindo's Supplemental Responses to First Set of Common Interrogatories; and (3) Aurobindo's Supplemental Response to First Set of Common Requests for Production filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
|
SO ORDERED, re #320 STIPULATION and Proposed Order Extending Discovery and Precluding Breckenridge from Launching at Risk; #321 STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Proposal for the Length of Briefing and the Format of a Preliminary Injunction Hearing to Thursday, January 17, 2019 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 1/17/19. (ntl)
|
|
SO ORDERED, re #318 Stipulation and Order Staying the Case as to Biocon. Signed by Judge Leonard P. Stark on 1/17/19. (ntl)
|
| Filing 324 Letter to the Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Preliminary Injunction Briefing and Related Issues - re #216 Scheduling Order,,. (Attachments: #1 Proposed Order)(Silver, Daniel) |
|
SO ORDERED, re #317 STIPULATION TO EXTEND TIME for Teva to Substantially Complete Document Production to February 5, 2019 filed by Teva Pharmaceuticals USA Inc. Signed by Judge Leonard P. Stark on 1/15/19. (ntl)
|
| Filing 323 NOTICE OF SERVICE of Defendants HEC Pharm Co., Ltd. and HEC Pharm USA Inc.s Second Supplemental Response to Plaintiffs First Set of Common Interrogatories 1, 3-7, HEC Pharm Co., Ltd. and HEC Pharm USA Inc.s Fed. R. CIv. P. 26(a)(1) Initial Disclosures (Amended), and Defendants HEC Pharm Group and HEC Pharm USA, Inc.s Second Supplemental Response to Plaintiffs First Set of Common Requests for the Production of Documents and Things 1-30 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 322 NOTICE OF SERVICE of Second Supplemental Discovery Disclosures Pursuant to the District of Delaware's Default Standard for Discovery filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Filing 321 STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Proposal for the Length of Briefing and the Format of a Preliminary Injunction Hearing to Thursday, January 17, 2019 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 320 STIPULATION and Proposed Order Extending Discovery and Precluding Breckenridge from Launching at Risk by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 319 NOTICE OF SERVICE of (1) Third Supplemental Responses to First Set of Common Interrogatories and (2) Second Supplemental Responses to First Set of Common Requests for Production filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Filing 318 STIPULATION and Proposed Order Staying the Case as to Biocon by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 317 STIPULATION TO EXTEND TIME for Teva to Substantially Complete Document Production to February 5, 2019 - filed by Teva Pharmaceuticals USA Inc.. (Keller, Karen) |
| Filing 316 NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's First Supplemental Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 315 NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Amended Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 314 NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Amended Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery, Including Discovery of Electronically Stored Information filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Filing 313 NOTICE OF SERVICE of Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s Second Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Filing 312 NOTICE OF SERVICE of (1) Defendant Accord Healthcare, Inc.'s Second Supplemental Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30] (No. 25); (2) Defendants Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc.'s Second Supplemental Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30] (No. 25); and (3) Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Second Supplemental Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30] (No. 25) filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
|
SO ORDERED, re #309 STIPULATION and Proposed Order Extending Discovery and Precluding Glenmark from Launching at Risk. Signed by Judge Leonard P. Stark on 1/10/19. (ntl)
|
| Filing 311 NOTICE OF SERVICE of (1). BIONPHARMAS SECOND AMENDED INITIAL PARAGRAPH 3 DISCLOSURES; (2). BIONPHARMAS SECOND AMENDED RESPONSES TO FIRST SET OF REQUESTS FOR PRODUCTION (NOS. 1-30); (3). BIONPHARMAS SECOND AMENDED RESPONSES TO FIRST SET OF INTERROGATORIES (NOS. 1-7); (4) HETEROS SECOND AMENDED INITIAL PARAGRAPH 3 DISCLOSURES; (5) HETEROS SECOND AMENDED RESPONSES TO FIRST SET OF REQUESTS FOR PRODUCTION (NOS. 1-30); (6) HETEROS SECOND AMENDED RESPONSES TO FIRST SET OF INTERROGATORIES (NOS. 1-7); (7) PRINSTONS SECOND AMENDED INITIAL PARAGRAPH 3 DISCLOSURES; (8) PRINSTONS SECOND AMENDED RESPONSES TO FIRST SET OF REQUESTS FOR PRODUCTION (NOS. 1-30); AND (9). PRINSTONS SECOND AMENDED RESPONSES TO FIRST SET OF INTERROGATORIES (NOS. 1-7) filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Filing 310 NOTICE OF SERVICE of Defendants Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc.'s Amended Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery, Including Discovery of Electronically Stored Information filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Filing 309 STIPULATION and Proposed Order Extending Discovery and Precluding Glenmark from Launching at Risk by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Pro Hac Vice Attorney Kimberly A. Beis for Biocon Limited and Biocon Pharma, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ddp) |
| Filing 308 Official Transcript of Telephone Conference held on December 21, 2018 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/28/2019. Redacted Transcript Deadline set for 2/7/2019. Release of Transcript Restriction set for 4/8/2019.(bpg) |
| Filing 307 NOTICE OF SERVICE of Defendant Accord Healthcare Inc.'s (1) Second Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories (Nos. 3 and 7); and (2) Amended Delaware Paragraph 3 Disclosures filed by Accord Healthcare Inc..(Ormerod, Eve) |
| Filing 306 NOTICE OF SERVICE of Defendants' Second Joint Interrogatories to Plaintiff (Nos. 14-19) filed by Actavis Elizabeth LLC, Teva Pharmaceuticals USA Inc..(Hoeschen, Nathan) |
| Filing 305 NOTICE OF SERVICE of 1) Defendants' Second Supplemental Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery; 2) Defendants' Supplemental Objections and Responses to Plaintiff's First Set of Common Requests for Production (Nos. 7-16, 18, 20, 22-25); and 3) Defendants' Supplemental Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1, 3-7) filed by Actavis Elizabeth LLC, Teva Pharmaceuticals USA Inc..(Hoeschen, Nathan) |
|
SO ORDERED, re #302 Stipulation and Order Staying the Case as to Heritage Pharmaceuticals Inc., Emcure Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 12/26/18. (ntl)
|
| Filing 304 NOTICE OF SERVICE of Second Supplemental Response to First Set of Common Interrogatories filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Minute Entry for proceedings held before Judge Leonard P. Stark - Discovery Teleconference held on 12/21/2018. (Court Reporter B. Gaffigan.) (ntl) |
| Filing 303 NOTICE OF SERVICE of Novartiss Objections and Responses to Defendants Third Joint Requests for Production to Plaintiff (Nos. 65-76) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 302 STIPULATION and Proposed Order Staying the Case as to Heritage and Emcure by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc.. (Haney, Megan) |
| Filing 301 Letter to The Honorable Leonard P. Stark from Eve H. Ormerod regarding Responsive Position with respect to Discovery Dispute - re 289 Order,,,,. (Attachments: #1 Exhibits 1-11)(Ormerod, Eve) |
| Filing 300 NOTICE OF SERVICE of (1) Defendant Accord Healthcare, Inc.'s Supplemental Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30]; (2) Defendants Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc.'s Supplemental Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30]; and (3) Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Supplemental Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30] filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Filing 299 NOTICE OF SERVICE of Defendant Alkem's First Supplemental Objections and Responses to Plaintiff's First Set of Common Requests for Production filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Filing 298 Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Zydus's Response to Plaintiff's December 12, 2018 Letter - re #287 Letter. (Attachments: #1 Exhibit 1)(Phillips, John) |
| Filing 297 Letter to The Honorable Leonard P. Stark from Kenneth L. Dorsney regarding Discovery Dispute - re #287 Letter. (Dorsney, Kenneth) |
| Filing 296 [SEALED] Letter to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding Regarding Mylan Pharmaceuticals, Inc.'s Response to Novartis Concerning Redaction Dispute - re #286 Letter. (Cottrell, Frederick) |
| Filing 295 DECLARATION re #294 Letter -- executed by George J. Barry III -- by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth) |
| Filing 294 Letter to The Honorable Leonard P. Stark from Kenneth L. Dorsney regarding Aurobindo's responsive discovery dispute letter. (Dorsney, Kenneth) |
| Filing 293 NOTICE OF SERVICE of Defendants Consolidated Invalidity Contentions Regarding U.S. Patent No. 9,187,405 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 292 NOTICE OF SERVICE of Defendant Accord Healthcare Inc.'s Second Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) filed by Accord Healthcare Inc..(Ormerod, Eve) |
| Filing 291 DECLARATION re #290 Letter of Paul Torchia by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 1-8)(Silver, Daniel) |
| Filing 290 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Plaintiffs Dispute with Accord, Dr. Reddy's, and Torrent - re 289 Order,,,,. (Silver, Daniel) |
|
Filing 289
ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter (D.I. 271), IT IS HEREBY ORDERED that a teleconference is scheduled for December 21, 2018 at 1:00 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than December 17, 2018, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than December 18, 2018, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 12/13/18. (ntl)
|
| Filing 288 DECLARATION re #287 Letter of Paul Torchia by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 1-17)(Silver, Daniel) |
| Filing 287 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Plaintiffs Disputes with Zydus, Aurobindo, Hetero, Bionpharma and Prinston. (Silver, Daniel) |
| Filing 286 [SEALED] Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Plaintiffs Dispute with Mylan. (Attachments: #1 Exhibit A & B, #2 Certificate of Service)(Silver, Daniel) |
| Filing 285 NOTICE OF SERVICE of Responses to Plaintiffs First Set of Interrogatories (1-3) filed by Ezra Ventures, LLC.(Stamoulis, Stamatios) |
| Filing 284 NOTICE OF SERVICE of Responses to Plaintiffs First Set of Interrogatories (1-3) filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 283 NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's First Set of Interrogatories to Mylan Pharmaceuticals Inc. [Nos. 1-3] filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Filing 282 NOTICE OF SERVICE of Objections and Responses to Plaintiffs First Set of Interrogatories Nos. 1-3 filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd..(Farnan, Kelly) |
| Filing 281 NOTICE OF SERVICE of (1) Defendant Accord Healthcare, Inc.'s Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-3); (2) Defendants Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc.'s Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-3); and (3) Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-3) filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Filing 280 NOTICE OF SERVICE of (1) Defendants' Responses and Objections to Plaintiffs' First Set of Interrogatories to Teva and Actavis (Nos. 1-3) filed by Teva Pharmaceuticals USA Inc..(Keller, Karen) |
| Filing 279 NOTICE OF SERVICE of Defendants' Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-3) to Emcure Pharmaceuticals and Heritage Pharmaceuticals Inc. filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc..(Haney, Megan) |
| Filing 278 NOTICE OF SERVICE of (1) Defendants Biocon Limited and Biocon Pharma, Inc.'s Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories 1-7; and (2) Defendants Biocon Limited and Biocon Pharma, Inc.'s Objections and Responses to Plaintiff's First Set of Interrogatories to Biocon (1-3) filed by Biocon Limited, Biocon Pharma, Inc..(Haney, Megan) |
| Filing 277 NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiff's First Set of Interrogatories (1-3) to Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 276 NOTICE OF SERVICE of Defendants Glenmark Pharmaceuticals, Inc., USA and Glenmark Pharmaceuticals Limited's Objections and Responses to Plaintiff's First Set of Interrogatories Directed to Glenmark (Nos. 1- 3) filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited.(Poff, Adam) |
| Filing 275 NOTICE OF SERVICE of Bionpharma, Hetero and Prinston's responses to Plaintiff's First Set of Interrogatories (Nos. 1-3) filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Filing 274 NOTICE OF SERVICE of Aurobindo's response to Plaintiff's First Set of Interrogatories (Nos. 1-3) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Filing 273 NOTICE OF SERVICE of Alkem's responses to Plaintiff's First Set of Interrogatories (Nos. 1-3) filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
|
Filing 272
ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter (See D.I. 243, 265, 266, 267), IT IS HEREBY ORDERED that a teleconference is scheduled for December 21, 2018 at 1:00 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than December 12, 2018, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than December 14, 2018, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 12/10/18. (ntl)
|
| Filing 271 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Request the Scheduling of a Discovery Teleconference. (Silver, Daniel) |
| Filing 270 NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s First Supplemental Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things to All Defendants (Nos. 1-30) filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Filing 269 NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s First Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories to All Defendants (Nos. 1-7) filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Pro Hac Vice Attorney Bryan D. Beel for Mylan Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) |
|
SO ORDERED, re #268 MOTION for Pro Hac Vice Appearance of Attorney Bryan D. Beel filed by Mylan Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 12/6/18. (ntl)
|
| Filing 268 MOTION for Pro Hac Vice Appearance of Attorney Bryan D. Beel - filed by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Filing 267 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Scheduling a Discovery Conference. (Silver, Daniel) |
| Filing 266 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Scheduling a Discovery Conference. (Silver, Daniel) |
| Filing 265 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Scheduling a Discovery Teleconference. (Silver, Daniel) |
| Filing 264 NOTICE OF SERVICE of Defendants HEC Pharm Co., Ltd. and HEC Pharm USA Inc.s First Supplemental Response to Plaintiffs First Set of Common Requests for the Production of Documents and Things 1-30 and Defendants HEC Pharm Co., Ltd and HEC Pharm USA Inc.s First Supplemental Response to Plaintiffs First Set of Common Interrogatories 1-7 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 263 NOTICE OF SERVICE of Alkem's First Supplemental Responses to First Set of Common Interrogatories (Nos. 1-6) filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Filing 262 AFFIDAVIT of Service for Subpoena Duces Tecum served on Peter Arthur Calabresi, M.D. on November 26, 2018, filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| Filing 261 NOTICE OF SERVICE of Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) and Defendant Accord Healthcare Inc.'s Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Filing 260 NOTICE OF SERVICE of Novartiss Objections and Responses to Defendants Second Joint Requests for Production to Plaintiff (Nos. 60-64) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 259 NOTICE OF SERVICE of Third Joint Requests for Production (Nos. 65-76) filed by Alkem Laboratories Ltd., Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Filing 258 NOTICE OF SERVICE of Subpoena Duces Tecum to Peter Arthur Calabresi, M.D. filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Attachments: #1 Exhibit 1 to Notice of Subpoena, #2 Exhibit A to Subpoena)(Ormerod, Eve) |
| Filing 257 NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Pro Hac Vice Attorney Alan H. Pollack for Accord Healthcare Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) |
| Filing 256 NOTICE OF SERVICE of (1) Bionpharma, Hetero and Prinston's Amended Responses to Plaintiff's First Set of Common Interrogatories (No. 7); and (2) Bionpharma, Hetero and Prinston's Amended Responses to Plaintiff's First Set of Common Requests for Production (Nos. 8-10, 18) filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Filing 255 Letter to the Honorable Leonard P. Stark from Stamatios Stamoulis regarding Regarding Order on Discovery Dispute Request - re 239 Order,. (Stamoulis, Stamatios) |
| Filing 254 NOTICE OF SERVICE of Defendants Bionpharma, Hetero and Prinston's Amended Paragraph 3 Disclosures filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Filing 253 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Request for Relief - re #244 Letter. (Silver, Daniel) |
|
SO ORDERED, re #249 Stipulation and Order to Stay Between Plaintiff and Sun. Signed by Judge Leonard P. Stark on 11/15/18. (ntl)
|
|
SO ORDERED, re #250 MOTION for Pro Hac Vice Appearance of Attorney Alan H. Pollack filed by Dr. Reddys Laboratories, Inc., Accord Healthcare Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Dr. Reddys Laboratories, Ltd. Signed by Judge Leonard P. Stark on 11/15/18. (ntl)
|
| Filing 252 NOTICE OF SERVICE of Defendant Ezra Ventures LLCs Amended Responses to Plaintiffs First Set of Common Requests for the Production of Documents and Things to All Defendants and Defendant Ezra Ventures LLCs Amended Responses to Plaintiffs First Set of Common Interrogatories to All Defendants filed by Ezra Ventures, LLC.(Stamoulis, Stamatios) |
| Filing 251 NOTICE OF SERVICE of Novartiss Objections and Responses to Accord, DRL, and Torrents Document Requests Nos. 1-3 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 250 MOTION for Pro Hac Vice Appearance of Attorney Alan H. Pollack - filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| Filing 249 STIPULATION and Proposed Order to Stay Between Plaintiff and Sun by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 248 REDACTED VERSION of #247 Letter to The Honorable Leonard P. Stark from Kenneth L. Dorsney responding to Plaintiff's Novenber 13, 2018 letter regarding meet and confer with Alkem by Alkem Laboratories Ltd.. (Dorsney, Kenneth) (Main Document 248 replaced on 11/14/2018) (ntl). |
| Filing 247 [SEALED] Letter to The Honorable Leonard P. Stark from Kenneth L. Dorsney regarding response to Plaintiff's November 13, 2018 letter concerning meet and confer. (Dorsney, Kenneth) (Main Document 247 replaced on 11/14/2018) (ntl). |
|
SO ORDERED, re #235 Stipulation of Dismissal -- Party MSN Pharmaceuticals Inc., MSN Pharmaceuticals Inc., Nostrum Laboratories Inc., Nostrum Laboratories Inc., Nostrum Pharmaceuticals, LLC, Nostrum Pharmaceuticals, LLC, MSN Laboratories Private Limited and MSN Laboratories Private Limited terminated. Attorney David J. Austin and David L. Finger terminated. Signed by Judge Leonard P. Stark on 11/8/18. (ntl)
|
|
SO ORDERED, re #237 Stipulation and Order to Stay Between Plaintiff and Apotex. Signed by Judge Leonard P. Stark on 11/8/18. (ntl)
|
| CORRECTING ENTRY: Corrected documents added to D.I. 247 & 248 per request of counsel. (ntl) |
| Filing 246 NOTICE OF SERVICE of Defendants Emcure Pharmaceuticals and Heritage Pharmaceuticals Inc.'s Supplemental Disclosures Pursuant to Delaware Default Standard for Discovery Paragraph 3 filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc..(Haney, Megan) |
| Filing 245 NOTICE OF SERVICE of Subpoenas filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 244 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Meet and Confer with Defedant Alkem Laboratories Ltd.. (Attachments: #1 Exhibit 1)(Silver, Daniel) |
| Filing 243 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Discovery Dispute Teleconference. (Silver, Daniel) |
| Filing 242 NOTICE OF SERVICE of Supplemental Initial Disclosures of Defendants Biocon Limited and Biocon Pharma Inc. Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Biocon Limited, Biocon Pharma, Inc..(Haney, Megan) |
| Filing 241 NOTICE OF SERVICE of Plaintiffs First Set of Interrogatories (1-3) to Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 240 NOTICE OF SERVICE of Responses to Plaintiffs First Set of Requests for the Production of Documents and Things to Defendant Ezra Ventures LLC filed by Ezra Ventures, LLC.(Stamoulis, Stamatios) |
|
Filing 239
ORAL ORDER: Having reviewed the parties' letters (D.I. 234, 236), IT IS HEREBY ORDERED that the parties shall meet and confer and, no later than November 16, advise the Court by joint letter whether any party believes a ripe discovery dispute requires judicial resolution. Thereafter, the Court will determine whether to schedule a discovery dispute teleconference. ORDERED by Judge Leonard P. Stark on 11/7/18. (ntl)
|
| Filing 238 OBJECTIONS by Novartis Pharmaceuticals Corporation OPPOSITION TO THE MOTION TO STAY AND FOR JOINDER IN APOTEXS MOTION TO STAY BY THE SUN DEFENDANTS (D.I. 33 IN C.A. NO. 18-1040-LPS). (Attachments: #1 Exhibit A)(Silver, Daniel) |
|
SO ORDERED, re #229 Stipulated Amendment to Protective Order Between Novartis and Glenmark re #217 Protective Order. Signed by Judge Leonard P. Stark on 11/5/18. (ntl)
|
| Filing 237 STIPULATION -- Stipulation and Proposed Order to Stay Between Plaintiff and Apotex by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 236 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Responsive Letter - re #234 Letter. (Silver, Daniel) |
| Filing 235 STIPULATION of Dismissal Against Defendants Nostrum Laboratories, Inc., Nostrum Pharmaceuticals, LLC, MSN Laboratories Private Limited, and MSN Pharmaceuticals Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 234 Letter to the Honorable Leonard P. Stark from Stamatios Stamoulis regarding Requesting Discovery Dispute Conference. (Attachments: #1 Exhibit A, #2 Exhibit B)(Stamoulis, Stamatios) |
| Filing 233 REDACTED VERSION of #224 Letter by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Filing 232 REDACTED VERSION of #219 Letter, by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
|
Filing 231
ORDER Setting Mediation Conference: A Telephone Conference is set for 12/3/2018 at 11:00 AM before Judge Christopher J. Burke to discuss ADR. Signed by Judge Christopher J. Burke on 11/2/2018. (dlb)
|
| Filing 230 REDACTED VERSION of #220 Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 229 STIPULATION Stipulated Amendment to Protective Order Between Novartis and Glenmark re #217 Protective Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 228 NOTICE OF SERVICE of Responses to Plaintiffs First Set of Requests for the Production of Documents and Things to Defendants HEC Pharm Co., Ltd and HEC Pharm USA Inc. filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 227 NOTICE OF SERVICE of Defendant Actavis Elizabeth LLC'S Objections and Responses to Plaintiffs First Set of Requests for Production (No. 1) filed by Actavis Elizabeth LLC.(Hoeschen, Nathan) |
| Filing 226 NOTICE OF SERVICE of Plaintiff's Preliminary Infringement Contentions for Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 225 [SEALED] Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Responsive Letter - re #219 Letter,. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
| Filing 224 [SEALED] Letter to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding response to Novartis's letter of October 25, 2018 - re #220 Letter,. (Cottrell, Frederick) |
| Filing 223 REDACTED VERSION of #207 Declaration by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 1-2)(Ewing, Alexandra) |
| Filing 222 REDACTED VERSION of #206 Reply Brief by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Filing 221 NOTICE OF SERVICE of Defendants Breckenridge Pharmaceutical, Inc. and Standard Chemical & Pharmaceutical Co., Ltd.'s Supplemental Initial Disclosures filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd..(Farnan, Kelly) |
| Pro Hac Vice Attorney Robert F. Vroom for Breckenridge Pharmaceutical, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) |
| Filing 220 [SEALED] Letter to the Honorable Leonard P. Stark from Daniel M. Silver regarding Opposition to Motion to Dismiss on Venue Grounds by Mylan. (Attachments: #1 Exhibit A - I, #2 Declaration of Richard Trenchard, #3 Certificate of Service)(Silver, Daniel) |
| Filing 219 [SEALED] Letter to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding supplemental letter brief - re 209 Order,, #118 MOTION to Dismiss for Improper Venue , #119 Opening Brief in Support. (Cottrell, Frederick) |
|
Filing 218
ORDER FOR DISCOVERY, INCLUDING DISCOVERY OF ELECTRONICALLY STORED INFORMATION("ESI"). Signed by Judge Leonard P. Stark on 10/25/2018. (etg)
|
|
Filing 217
PROTECTIVE ORDER. Signed by Judge Leonard P. Stark on 10/25/2018. (etg)
|
|
Filing 216
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Fact Discovery completed by 6/4/2019. Status Report due by 1/25/2019. Claim Construction Opening Brief due by 2/28/2019. Claim Construction Answering Brief due by 4/2/2019. A Markman Hearing is set for 4/23/2019 at 02:00 PM in Courtroom 6B before Judge Leonard P. Stark. Proposed Pretrial Order due by 1/6/2020. A Pretrial Conference is set for 2/21/2020 at 04:00 PM in Courtroom 6B before Judge Leonard P. Stark. A Bench Trial is set for 3/2/2020 at 08:30 AM in Courtroom 6B before Judge Leonard P. Stark. Signed by Judge Leonard P. Stark on 10/25/2018. (etg)
|
|
Filing 215
ORAL ORDER: Having reviewed the parties' most recent submission relating to scheduling and the protective order (see C.A. No. 18-1038 D.I. 47), and considering the parties' earlier related submissions and the Court's discussion of the issues with the parties on October 16, the Court will today be docketing the scheduling order, protective order, and ESI order to govern these cases. The Court has exercised its discretion in the fashion it believes most reasonable to all involved, balancing important competing interests on each side. In particular, with respect to scheduling: the Court agrees with Novartis that there should be some time limit on Rule 30(b)(6) deposition hours but believes Novartis' proposed limit is too short; the Court agrees with Defendants' to allow lengthier depositions of inventors; and the Court agrees with Novartis to allow lengthier depositions of expert(s) who provide opinions on both infringement and validity. With respect to the protective order, the Court believes that good cause has been shown to preclude Plaintiffs' counsel who are in receipt of Defendants' protected information from participating in the drafting, crafting, or amending of any patent claims, and the Court believes its combination of provisions proposed by both sides has resulted in a mechanism for, when needed, the sharing and potential use of one Defendant's information against another Defendant, while providing adequate protections to all parties and not unduly risking burdening the Court. Ordered by Judge Leonard P. Stark on 10/25/2018. (etg)
|
| CORRECTING ENTRY: Referral for ADR to Judge Thynge was made in error. (cak) |
| CASE REFERRED to Magistrate Judge Christopher J. Burke for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at # http://www.ded.uscourts.gov/general-orders/magistrate-judges-standing-order-adr-mediation (cak) |
| Filing 214 Joint Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Rule 16 Teleconference. (Attachments: #1 Proposed Scheduling Order, #2 Proposed Protective Order, #3 Proposed ESI Order)(Silver, Daniel) |
| Filing 213 NOTICE OF SERVICE of Defendants' Second Set of Joint Requests for Production to Novartis (Nos. 60-64) filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Filing 212 Official Transcript of Telephone Conference held on October 16, 2018 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 11/13/2018. Redacted Transcript Deadline set for 11/23/2018. Release of Transcript Restriction set for 1/22/2019.(bpg) |
| Filing 211 NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s Supplemental Discovery Disclosures Pursuant to the District of Delaware's Default Standard for Discovery filed by Mylan Pharmaceuticals, Inc..(Cottrell, Frederick) |
| Filing 210 NOTICE OF SERVICE of Supplemental Initial Disclosures Pursuant to Paragraph 3 of the Delware Default Standard for Discovery filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
|
Filing 209
ORAL ORDER: The briefing on Defendant's motion to dismiss for improper venue having been completed, and the Court having recently issued an opinion granting a similar motion in another case (see Bristol-Meyers Squibb Co. v. Aurobindo Pharma USA Inc., No. 17-374 (D. Del. Oct. 18, 2018) ("BMS")), D.I. 382), IT IS HEREBY ORDERED that the parties shall provide supplemental letter briefs addressing the impact of the Court's BMS decision on the pending motion, according to the following schedule: (i) opening briefs not to exceed three pages each due on Thursday, October 25; and (ii) answering briefs not to exceed two pages each due on Friday, October 26. ORDERED by Judge Leonard P. Stark on 10/22/18. (ntl)
|
| Filing 208 NOTICE OF SERVICE of Subpoenas and Discovery Requests filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Subpoena to Mylan Specialty L.P., #2 Subpoena to Therese Guariano Fresconi)(Silver, Daniel) |
| Pro Hac Vice Attorney David J. Austin for MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., Nostrum Laboratories Inc., Nostrum Pharmaceuticals, LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) |
| Filing 207 [SEALED] DECLARATION re #206 Reply Brief (Declaration of Brandon M. White) by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 1-2)(Cottrell, Frederick) |
| Filing 206 [SEALED] REPLY BRIEF re #118 MOTION to Dismiss for Improper Venue filed by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
|
SO ORDERED, re #204 MOTION for Pro Hac Vice Appearance of Attorney Stephen P. Benson and Kimberly A. Beis filed by Biocon Limited, Biocon Pharma, Inc., #202 MOTION for Pro Hac Vice Appearance of Attorney Robert F. Vroom filed by Breckenridge Pharmaceutical, Inc. Signed by Judge Leonard P. Stark on 10/18/18. (ntl)
|
| Filing 205 NOTICE OF SERVICE of (1) Plaintiff's Objections and Responses to Defendants' First Joint Interrogatories to Plaintiff (Nos. 1-13) and (2) Novartis's Objections and Responses to Defendants' First Joint Requests for Production to Novartis (Nos. 1-59) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Minute Entry for proceedings held before Judge Leonard P. Stark - Discovery/Scheduling teleconference held on 10/16/2018 (Court Reporter B. Gaffigan.) Associated Cases: 1:18-cv-01038-LPS, 1:18-cv-01039-LPS, 1:18-cv-01040-LPS, 1:18-cv-01043-LPS (ntl) |
| Filing 204 MOTION for Pro Hac Vice Appearance of Attorney Stephen P. Benson and Kimberly A. Beis - filed by Biocon Limited, Biocon Pharma, Inc.. (Attachments: #1 Certification of Stephen P. Benson, #2 Certification of Kimberly A. Beis)(Haney, Megan) |
|
Filing 203
ORAL ORDER: IT IS HEREBY ORDERED that the Discovery/Scheduling teleconference today will begin at 3:15 p.m. ORDERED by Judge Leonard P. Stark on 10/16/18. Associated Cases: 1:18-cv-01038-LPS, 1:18-cv-01039-LPS, 1:18-cv-01040-LPS, 1:18-cv-01043-LPS (ntl)
|
| Filing 202 MOTION for Pro Hac Vice Appearance of Attorney Robert F. Vroom - filed by Breckenridge Pharmaceutical, Inc.. (Farnan, Kelly) |
| Pro Hac Vice Attorney Christie R.W. Matthaei for Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) |
|
SO ORDERED, re #200 MOTION for Pro Hac Vice Appearance of Attorney David J. Austin filed by Nostrum Laboratories Inc., MSN Laboratories Private Limited, Nostrum Pharmaceuticals, LLC, MSN Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 10/16/18. (ntl)
|
| Filing 201 NOTICE OF SERVICE of Defendants Accord Healthcare, Inc., Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s First Set of Requests for the Production of Documents and Things [Nos. 1-3] filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Filing 200 MOTION for Pro Hac Vice Appearance of Attorney David J. Austin - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., Nostrum Laboratories Inc., Nostrum Pharmaceuticals, LLC. (Attachments: #1 Certification of David J. Austin)(Finger, David) |
| Pro Hac Vice Attorney Stephen R. Auten,Roshan Shrestha for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) |
| Filing 199 Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Defendants' Response to Plaintiff's Opening Discovery Dispute Letter - re (38 in 1:18-cv-01038-LPS, 196 in 1:18-cv-01043-LPS, 27 in 1:18-cv-01039-LPS, 25 in 1:18-cv-01040-LPS) Letter. (Attachments: #1 Exhibit 1 - 4)(Phillips, John) |
| Filing 198 Letter to the Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Response to Defendants' October 11, 2016 Letter - re (39 in 1:18-cv-01038-LPS, 197 in 1:18-cv-01043-LPS, 26 in 1:18-cv-01040-LPS, 28 in 1:18-cv-01039-LPS) Letter. (Attachments: #1 Exhibit E)(Silver, Daniel) |
| Pro Hac Vice Attorney Charles A. Weiss for Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) |
| Filing 197 Letter to the Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Defendants' Opening Dispute Letter. (Phillips, John) |
| Filing 196 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Disputes About the Proposed Scheduling Order and Proposed ESI and Protective Orders. (Attachments: #1 Exhibit A - D)(Silver, Daniel) |
| Filing 195 NOTICE OF SERVICE of (1) Defendants Biocon Limited and Biocon Pharma, Inc.'s Objections and Responses to Plaintiff's First Set of Common Interrogatories 1-7; and (2) Defendants Biocon Limited and Biocon Pharma, Inc.'s Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things 1-30 filed by Biocon Limited, Biocon Pharma, Inc..(Haney, Megan) |
| Filing 194 Letter to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding Mylan Pharmaceuticals Inc.'s Response to Novartis' letter regarding Opposition to Mylan Pharmaceuticals Inc.'s Motion to Dismiss for Improper Venue - re #191 Letter. (Cottrell, Frederick) |
| Filing 193 NOTICE of Appearance by Alexandra M. Ewing on behalf of Mylan Pharmaceuticals, Inc. (Ewing, Alexandra) |
|
SO ORDERED, re #188 MOTION for Pro Hac Vice Appearance of Attorney Christie R.W. Matthaei filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited. Signed by Judge Leonard P. Stark on 10/11/2018. (etg)
|
|
SO ORDERED, re #189 MOTION for Pro Hac Vice Appearance of Attorney Charles A. Weiss filed by Hetero Labs Limited Unit-V, Bionpharma Inc., Hetero USA Inc., Hetero Labs Limited, Prinston Pharmaceutical Inc.. Signed by Judge Leonard P. Stark on 10/11/2018. (etg)
|
|
Filing 192
ORAL ORDER: IT IS HEREBY ORDERED that the Teleconference set for 10/16/18 at 02:00 PM is RESCHEDULED for 10/16/2018 at 2:45 PM before Judge Leonard P. Stark. Ordered by Judge Leonard P. Stark on 10/10/2018. (etg)
|
| Pro Hac Vice Attorney Shannon M. Bloodworth for Mylan Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) |
| Filing 191 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Novartis Opposition to Mylan Pharmaceuticals Inc.'s Motion to Dismiss for Improper Venue. (Silver, Daniel) |
|
Filing 190
ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a discovery and scheduling teleconference is scheduled for October 16, 2018 at 2:00 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than October 11, 2018, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than October 12, 2018, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 10/9/2018. (etg)
|
| Filing 189 MOTION for Pro Hac Vice Appearance of Attorney Charles A. Weiss - filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc.. (Dorsney, Kenneth) |
| Filing 188 MOTION for Pro Hac Vice Appearance of Attorney Christie R.W. Matthaei - filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited. (Poff, Adam) |
| Filing 187 ANSWER to #146 Answer to Complaint, Counterclaim as to Defendants Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Limited by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 186 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Emcure Pharmaceuticals Ltd. for Heritage Pharmaceuticals Inc. filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc.. (Phillips, John) |
| Filing 185 ANSWER to #1 Complaint,,,,, by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc..(Phillips, John) |
| Filing 184 NOTICE OF SERVICE of Defendant Glenmark Pharmaceuticals, Inc., USA and Glenmark Pharmaceuticals Limiteds Objections and Responses to: 1) Plaintiffs First Set of Common Requests for the Production of Documents and Things (Nos. 1 30); and 2) Plaintiffs First Set of Common Interrogatories (Nos. 1- 7) filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited.(Poff, Adam) |
|
SO ORDERED, re #170 Stipulation of Dismissal filed by Novartis Pharmaceuticals Corporation -- Party Par Pharmaceutical Inc. terminated. Attorney Tyler E. Cragg; David H. Silverstein; Aziz Burgy and Ricardo S. Camposanto terminated. Signed by Judge Leonard P. Stark on 10/4/18. (ntl)
|
|
SO ORDERED, re #180 STIPULATION TO EXTEND TIME for Mylan Pharmaceuticals to file reply brief in support of its Motion to Dismiss for Improper Venue to October 19, 2018 filed by Mylan Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 10/5/18. (ntl)
|
| Filing 183 NOTICE OF SERVICE of (1) Defendant Mylan Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things to All Defendants [Nos. 1-30]; and (2) Defendant Mylan Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's First Set of Common Interrogatories to All Defendants [Nos. 1-7] filed by Mylan Pharmaceuticals, Inc..(Rawnsley, Jason) |
| Filing 182 NOTICE OF SERVICE of Responses to Plaintiffs First Set of Common Interrogatories to All Defendants and Responses to Plaintiffs First Set of Common Requests for the Production of Documents and Things to All Defendants filed by Ezra Ventures, LLC.(Stamoulis, Stamatios) |
| Filing 181 NOTICE OF SERVICE of Responses to Plaintiffs First Set of Common Interrogatories to All Defendants and Responses to Plaintiffs First Set of Common Requests for the Production of Documents and Things to All Defendants filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 180 STIPULATION TO EXTEND TIME for Mylan Pharmaceuticals to file reply brief in support of its Motion to Dismiss for Improper Venue to October 19, 2018 - filed by Mylan Pharmaceuticals, Inc.. (Rawnsley, Jason) |
| Filing 179 NOTICE OF SERVICE of Defendants Breckenridge Pharmaceutical, Inc. and Standard Chemical & Pharmaceutical Co., Ltd.'s: (1) Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things 1-30 and (2) Objections and Responses to Plaintiff's First Set of Common Interrogatories 1-7 filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd..(Farnan, Kelly) |
| Filing 178 NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s (1) Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30]; and (2) Responses and Objections to Plaintiff's First Set of Common Interrogatories [Nos. 1-7] filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Filing 177 NOTICE OF SERVICE of Defendants Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc.'s (1) Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30]; and (2) Responses and Objections to Plaintiff's First Set of Common Interrogatories [Nos. 1-7] filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Filing 176 NOTICE OF SERVICE of Defendant Accord Healthcare, Inc.'s (1) Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30]; and (2) Responses and Objections to Plaintiff's First Set of Common Interrogatories [Nos. 1-7] filed by Accord Healthcare Inc..(Ormerod, Eve) |
| Filing 175 NOTICE OF SERVICE of (1) Defendants Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's First Set of Common Interrogatories; and (2) Defendants Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things 1-30 filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc..(Haney, Megan) |
| Filing 174 NOTICE OF SERVICE of (1) Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiff's First Set of Common Interrogatories to All Defendants; and (2) Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 173 NOTICE OF SERVICE of (1) Aurobindo's Responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-7); and (2) Aurobindo's Responses to Plaintiff's First Set of Common Requests for Production (Nos. 1-30) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Filing 172 NOTICE OF SERVICE of (1) Responses to First Set of Common Requests for Production and (2) Responses to First Set of Common Interrogatories filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Filing 171 NOTICE OF SERVICE of (1) Bionpharma's responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-7); (2) Bionpharma's responses to Plaintiff's First Set of Common Requests for Production (Nos. 1-30); (3) Hetero's responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-7); (4) Hetero's responses to Plaintiff's First Set of Common Requests for Production (Nos. 1-30); (5) Prinston's responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-7); and (6) Prinston's responses to Plaintiff's First Set of Common Requests for Production (Nos. 1-30) filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Filing 170 STIPULATION of Dismissal Against Defendant Par Pharmaceutical, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 169 REDACTED VERSION of #164 Declaration of Robert W. Trenchard in support of Answering Brief in Opposition to Motion to Dismiss for Improper Venue by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 168 REDACTED VERSION of #163 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 167 ANSWER to #134 Answer to Complaint, Counterclaim as to Defendant HEC Pharm Co., Ltd and HEC Pharm USA Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 166 NOTICE OF SERVICE of Plaintiff's First Set of Requests for the Production of Documents and Things as to Defendants HEC Pharm Co., Ltd., HEC Pharm USA Inc., and Ezra Ventures LLC filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 165 NOTICE OF SERVICE of (1) PLAINTIFFS VENUE-RELATED REQUESTS FOR THE PRODUCTION OF DOCUMENTS AND THINGS TO MYLAN PHARMACEUTICALS INC.; (2) PLAINTIFFS VENUE-RELATED INTERROGATORIES TO DEFENDANT MYLAN PHARMACEUTICALS INC.; (3) NOTICE OF DEPOSITION OF VENUE-RELATED 30(B)(6) DEPOSITION OF MYLAN PHARMACEUTICALS INC.; (4) SUBPOENAS TO MYLAN HOLDINGS INC. ; AND (5) SUBPOENAS TO MYLAN SECURITIZATION LLC filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 164 [SEALED] DECLARATION re #163 Answering Brief in Opposition, of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit 1-5, #2 Certificate of Service)(Silver, Daniel) |
| Filing 163 [SEALED] ANSWERING BRIEF in Opposition re #118 MOTION to Dismiss for Improper Venue filed by Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 10/5/2018. (Attachments: #1 Certificate of Service)(Silver, Daniel) |
| Pro Hac Vice Attorney William R. Zimmerman and Kimberly A. Kennedy for Glenmark Pharmaceuticals Inc. and Glenmark Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) |
| Pro Hac Vice Attorney Howard S. Suh for Bionpharma Inc., Hetero USA Inc., and Prinston Pharmaceutical Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) |
| Pro Hac Vice Attorney Forrest M. McClellen for Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) |
| Pro Hac Vice Attorney Benjamin A. Katzenellenbogen for Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) |
|
SO ORDERED, re #152 MOTION for Pro Hac Vice Appearance of Attorney William R. Zimmerman, Benjamin A. Katzenellenbogen, Kimberly A. Kennedy and Forrest M. McClellan filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited. Signed by Judge Leonard P. Stark on 9/25/18. (ntl)
|
| Filing 162 Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding request to schedule a Rule 16 Conference. (Phillips, John) |
| Pro Hac Vice Attorney Steven J. Udick for HEC Pharm Co., Ltd. and HEC Pharm USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) |
| Filing 161 NOTICE OF SERVICE of Bionpharma, Hetero and Prinston's 26(a)(1) Initial Disclosures filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Filing 160 NOTICE OF SERVICE of 1) Defendants' Initial Disclosures; and 2) Glenmark's Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited.(Poff, Adam) |
|
SO ORDERED, re #138 STIPULATION TO EXTEND TIME Plaintiff Novartis Pharmaceuticals Corporations deadline to respond to Mylan Pharmaceuticals Inc.'s Motion to Dismiss for Improper Venue to September 28, 2018 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 9/18/18. (ntl)
|
| Filing 159 NOTICE OF SERVICE of Fed. R. Civ. P. 26(a)(1) Initial Disclosures and Disclosures Pursuant to Paragraph 3 of the Delaware Default Discovery Standard filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 158 NOTICE OF SERVICE of Disclosures Pursuant to Federal Rule of Civil Procedure 26(A)(1) and Paragraph 3 of the Default Standard for Discovery filed by Ezra Ventures, LLC.(Stamoulis, Stamatios) |
| Filing 157 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Requesting a Discovery Teleconference. (Silver, Daniel) |
| Filing 156 NOTICE OF SERVICE of Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) and Discovery Disclosures Pursuant to the District of Delaware Default Standard for Discovery filed by Mylan Pharmaceuticals, Inc..(Rawnsley, Jason) |
| Filing 155 NOTICE OF SERVICE of Rule 26(a)(1) Initial Disclosures and Paragraph 3 Disclosures filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd..(Farnan, Kelly) |
| Filing 154 NOTICE OF SERVICE of (1) PLAINTIFFS INITIAL DISCLOSURES PURSUANT TO FED. R. CIV. P. 26(a)(1) and (2) PLAINTIFFS RULE 3 DISCLOSURES filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 153 NOTICE OF SERVICE of (1) Zydus Pharmaceuticals (USA) and Cadila Healthcare Limited's Fed.R.Civ.P. 36(a)(1) Initial Disclosures; and (2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 152 MOTION for Pro Hac Vice Appearance of Attorney William R. Zimmerman, Benjamin A. Katzenellenbogen, Kimberly A. Kennedy and Forrest M. McClellan - filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited. (Poff, Adam) |
| Filing 151 NOTICE OF SERVICE of Defendant Par Pharmaceutical Inc.'s Rule 26(a)(1) Initial Disclosures filed by Par Pharmaceutical Inc..(Cragg, Tyler) |
| Filing 150 NOTICE OF SERVICE of (1) Defendants Emcure Pharmaceuticals and Heritage Pharmaceuticals Inc.'s Disclosures Pursuant to Delaware Default Standard for Discovery Paragraph 3; and (2) Initial Disclosures of Defendants Emcure Pharmaceuticals and Heritage Pharmaceuticals Inc. Pursuant to Fed. Ri. Civ. P. 26(a)(1) filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc..(Haney, Megan) |
| Filing 149 NOTICE OF SERVICE of Defendant Par Pharmaceutical Inc.'s Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Par Pharmaceutical Inc..(Cragg, Tyler) |
| Filing 148 NOTICE OF SERVICE of Defendants Accord Healthcare, Inc., Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Delaware Paragraph 3 Disclosures and Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Filing 147 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Glenmark Pharmaceuticals Limited for Glenmark Pharmaceuticals Inc., USA filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited. (Poff, Adam) |
| Filing 146 ANSWER to #1 Complaint,,,,, , COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited.(Poff, Adam) |
| Filing 145 NOTICE OF SERVICE of (1) Initial Disclosures of Defendants Biocon Limited and Biocon Pharma Inc.; and (2) Initial Disclosures of Defendants Biocon Limited and Biocon Pharma Inc. Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Biocon Limited, Biocon Pharma, Inc..(Haney, Megan) |
| Filing 144 NOTICE OF SERVICE of (1) Defendants' First Joint Interrogatories to Plaintiff (Nos. 1-13); and (2) Defendants' First Joint Requests for Production to Plaintiff (Nos. 1-59) filed by Biocon Limited, Biocon Pharma, Inc., Cadila Healthcare Limited, Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 143 NOTICE OF SERVICE of (1) Aurobindo's 26(a)(1) Initial Disclosures; and (2) Aurobindo's Paragraph 3 Disclosures filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Filing 142 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Alkem Laboratories Ltd.. (Dorsney, Kenneth) |
| Filing 141 ANSWER to #1 Complaint,,,,, by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Filing 140 NOTICE OF SERVICE of (1) Initial Disclosures Pursuant to Paragrah 3 of the Delaware Default Standard for Discovery and (2) Initial Disclosures Purusant to F.R.C.P. 26(a) for Patent No. '405 filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Filing 139 NOTICE OF SERVICE of Bionpharma, Hetero and Prinston's Paragraph 3 Disclosures filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Filing 138 STIPULATION TO EXTEND TIME Plaintiff Novartis Pharmaceuticals Corporations deadline to respond to Mylan Pharmaceuticals Inc.s Motion to Dismiss for Improper Venue to September 28, 2018 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 137 REDACTED VERSION of #120 Declaration of Keith Meckstroth by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 1)(Rawnsley, Jason) |
| Filing 136 REDACTED VERSION of #119 Opening Brief in Support of Mylan Pharmaceuticals Inc.'s Motion to Dismiss for Improper Venue by Mylan Pharmaceuticals, Inc.. (Rawnsley, Jason) |
|
SO ORDERED, re #115 MOTION for Pro Hac Vice Appearance of Attorney Steven J. Udick filed by HEC Pharm Group, HEC Pharm USA Inc., HEC Pharm Co., Ltd. Signed by Judge Leonard P. Stark on 9/14/18. (ntl)
|
| Filing 135 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent HEC Pharm Group for HEC Pharm Co., Ltd., HEC Pharm USA Inc. filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Filing 134 ANSWER to #1 Complaint,,,,, with Jury Demand , COUNTERCLAIM against All Plaintiffs by HEC Pharm USA Inc., HEC Pharm Group, HEC Pharm Co., Ltd..(Stamoulis, Stamatios) |
| Filing 133 NOTICE OF SERVICE of Bicon's Abbreviated New Drug Application filed by Biocon Limited, Biocon Pharma, Inc..(Haney, Megan) |
| Filing 132 NOTICE OF SERVICE of Defendants Glenmark Pharmaceuticals Inc., USA, and Glenmark Pharmaceuticals Limited's Abbreviated New Drug Application filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited.(Poff, Adam) |
|
Filing 131
ORDER re #117 MOTION for Leave to File Under Seal filed by Mylan Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 9/10/18. (ntl)
|
| Filing 130 NOTICE OF SERVICE of Aurobindo's Abbreviated New Drug Application filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
|
SO ORDERED, re #122 STIPULATION and Order to Remove Defendant HEC Pharm Group and Amend Caption to Reflect Same -- HEC Pharm Group terminated. Signed by Judge Leonard P. Stark on 9/10/18. (ntl)
|
| Filing 129 NOTICE OF SERVICE of Defendant Breckenridge Pharmaceutical, Inc.'s ANDA production, Bates stamped BPI-FINGO-000001 to BPI-FINGO-018645 filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd..(Farnan, Kelly) |
| Filing 128 NOTICE OF SERVICE of Abbreviated New Drug Application filed by Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Filing 127 NOTICE OF SERVICE of Abbreviated New Drug Application filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc..(Haney, Megan) |
| Filing 126 NOTICE OF SERVICE of Defendants Accord Healthcare, Inc., Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Abbreviated New Drug Applications filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Filing 125 NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application filed by Mylan Pharmaceuticals, Inc..(Rawnsley, Jason) |
| Filing 124 NOTICE OF SERVICE of Abbreviated New Drug Application filed by Ezra Ventures, LLC.(Stamoulis, Stamatios) |
| Filing 123 NOTICE OF SERVICE of Abbreviated New Drug Application filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Filing 122 STIPULATION to Remove Defendant HEC Pharm Group and Amend Caption to Reflect Same by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Filing 121 NOTICE OF SERVICE of Defendant Par Pharmaceutical's Abbreviated New Drug Application filed by Par Pharmaceutical Inc..(Cragg, Tyler) |
| Filing 120 [SEALED] DECLARATION re #118 MOTION to Dismiss for Improper Venue , #119 Opening Brief in Support of Keith Meckstroth by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Exhibit 1)(Rawnsley, Jason) |
| Filing 119 [SEALED] OPENING BRIEF in Support re #118 MOTION to Dismiss for Improper Venue filed by Mylan Pharmaceuticals, Inc..Answering Brief/Response due date per Local Rules is 9/21/2018. (Rawnsley, Jason) |
| Filing 118 MOTION to Dismiss for Improper Venue - filed by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Text of Proposed Order)(Rawnsley, Jason) |
| Filing 117 MOTION for Leave to File Under Seal - filed by Mylan Pharmaceuticals, Inc.. (Attachments: #1 Proposed Order)(Rawnsley, Jason) |
| Filing 116 NOTICE OF SERVICE of Alkem Laboratories, Ltd.'s ANDA production filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| CORRECTING ENTRY: Corrected document added to D.I. 115 per request of counsel. (ntl) |
| Filing 115 MOTION for Pro Hac Vice Appearance of Attorney Steven J. Udick - filed by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Stamoulis, Stamatios) (Main Document 115 replaced on 9/7/2018) (ntl). |
| Filing 114 ANSWER to #85 Answer to Complaint, Counterclaim as to Defendant Breckenridge Pharmaceutical, Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 113 NOTICE OF SERVICE of (1) Plaintiff's First Set of Common Requests for the Production of Documents and Things to All Defendants; and (2) Plaintiff's First Set of Common Interrogatories to All Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
|
SO ORDERED, re #108 Stipulation and Order Staying the Case as to Strides. Signed by Judge Leonard P. Stark on 9/4/18. (ntl)
|
| Filing 112 NOTICE OF SERVICE of (1) Plaintiffs' Initial Disclosures of Accused Products and Asserted Patents; and (2) The File History for the Asserted Patent filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 111 ANSWER to #80 Answer to Complaint,, Counterclaim, as to Defendants Nostrum Laboratories Inc., Nostrum Pharmaceuticals, LLC, MSN Laboratories Private Limited, and MSN Pharmaceuticals, Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 110 ANSWER to #69 Answer to Complaint, Counterclaim as to Defendant Hetero USA Inc., Hetero Labs Limited Unit-V, and Hetero Labs Limited by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 109 ANSWER to #69 Answer to Complaint, Counterclaim as to Defendant Aurobindo Pharma Limited by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 108 STIPULATION and Proposed Order Staying the Case as to Strides by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 107 ANSWER to #62 Answer to Complaint, Counterclaim as to Defendants Biocon Limited and Biocon Pharma, Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 106 ANSWER to #33 Answer to Complaint, Counterclaim as to Defendant Prinston Pharmaceutical Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 105 ANSWER to #41 Answer to Complaint, Counterclaim as to Defendant Ezra Ventures LLC by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Filing 104 ANSWER to #35 Answer to Complaint, Counterclaim as to Defendant Bionpharma Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
|
SO ORDERED, re #102 MOTION for Pro Hac Vice Appearance of Attorney Louis H. Weinstein filed by Dr. Reddys Laboratories, Inc., Accord Healthcare Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Dr. Reddys Laboratories, Ltd. Signed by Judge Leonard P. Stark on 8/28/18. (ntl)
|
| Pro Hac Vice Attorney Louis H. Weinstein for Accord Healthcare Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) |
| Filing 103 PROPOSED ORDER Proposed Scheduling Order by Novartis Pharmaceuticals Corporation. (Attachments: #1 Letter to the Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Proposed Scheduling Order)(Silver, Daniel) |
| Pro Hac Vice Attorney Cindy Chang for Emcure Pharmaceuticals added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg) |
| Pro Hac Vice Attorney Michael J. Gaertner,David B. Abramowitz,Carolyn A. Blessing for Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) |
|
SO ORDERED, re #101 Stipulation of Dismissal filed by Novartis Pharmaceuticals Corporation -- Party First Time US Generics LLC terminated. Signed by Judge Leonard P. Stark on 8/24/18. (ntl)
|
| Filing 102 MOTION for Pro Hac Vice Appearance of Attorney Louis H. Weinstein - filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
|
SO ORDERED, re #100 MOTION for Pro Hac Vice Appearance of Attorney Michael Cottler filed by Heritage Pharmaceuticals Inc., Emcure Pharmaceuticals, #99 MOTION for Pro Hac Vice Appearance of Attorney Elaine Herrmann Blais and Cindy Chang filed by Heritage Pharmaceuticals Inc., Emcure Pharmaceuticals. Signed by Judge Leonard P. Stark on 8/23/18. (ntl)
|
| Filing 101 STIPULATION of Dismissal Against Defendant First Time US Generics LLC by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 100 MOTION for Pro Hac Vice Appearance of Attorney Michael Cottler - filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc.. (Haney, Megan) |
| Filing 99 MOTION for Pro Hac Vice Appearance of Attorney Elaine Herrmann Blais and Cindy Chang - filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc.. (Haney, Megan) |
|
SO ORDERED, re #98 MOTION for Pro Hac Vice Appearance of Attorney George J. Barry III and Attorney Timothy H. Kratz filed by Aurobindo Pharma USA, Inc., Aurobindo Pharma Limited. Signed by Judge Leonard P. Stark on 8/22/18. (ntl)
|
| Filing 98 MOTION for Pro Hac Vice Appearance of Attorney George J. Barry III and Attorney Timothy H. Kratz - filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth) |
| Pro Hac Vice Attorney Brandon M. White for Mylan Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) |
|
SO ORDERED, re #97 MOTION for Pro Hac Vice Appearance of Attorney Mieke Malmerg, Paul Skiermont, and Sarah Spires filed by HEC Pharm Group, HEC Pharm USA Inc., HEC Pharm Co., Ltd. Signed by Judge Leonard P. Stark on 8/20/18. (ntl)
|
| Pro Hac Vice Attorney Sarah E. Spires,Mieke Malmberg,Paul J. Skiermont for HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) |
| Filing 97 MOTION for Pro Hac Vice Appearance of Attorney Mieke Malmerg, Paul Skiermont, and Sarah Spires - filed by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Filing 96 NOTICE of Appearance by Megan C. Haney on behalf of Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc. (Haney, Megan) |
| Filing 95 NOTICE of Appearance by John C. Phillips, Jr on behalf of Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc. (Phillips, John) |
| Pro Hac Vice Attorney Alejandro Menchaca,Aaron F. Barkoff for Ezra Ventures, LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) |
| Pro Hac Vice Attorney Jonathan B. Turpin for Zydus Pharmaceuticals (USA) Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) |
|
SO ORDERED, re #93 MOTION for Pro Hac Vice Appearance of Attorney Jonathan B. Turpin filed by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Limited, #94 MOTION for Pro Hac Vice Appearance of Attorney Shannon M. Bloodworth and Brandon M. White filed by Mylan Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 8/16/18. (ntl)
|
|
SO ORDERED, re #91 Joint STIPULATION Extend Time To Respond to the Complaint to September 12, 2018 for Defendants HEC Pharm Co., Ltd., HEC Pharm Group and HEC Pharm USA Inc. filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 8/16/18. (ntl)
|
|
SO ORDERED, re #89 Joint STIPULATION and [Proposed] Order Dismissing Without Prejudice Defendant Intas Pharmaceuticals Ltd. and Amending Caption to Reflect Same -- Party Intas Pharmaceuticals Limited terminated. Signed by Judge Leonard P. Stark on 8/16/18. (ntl)
|
| Filing 94 MOTION for Pro Hac Vice Appearance of Attorney Shannon M. Bloodworth and Brandon M. White - filed by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Filing 93 MOTION for Pro Hac Vice Appearance of Attorney Jonathan B. Turpin - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
| Filing 92 MOTION for Pro Hac Vice Appearance of Attorney Michael J. Gaertner, David B. Abramowitz, Carolyn A. Blessing and Emily L. Savas - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
|
SO ORDERED, re #90 MOTION for Pro Hac Vice Appearance of Attorney Stephen R. Auten, Attorney Richard T. Ruzich, Attorney Jaimin H. Shah and Attorney Roshan P. Shrestha filed by Alkem Laboratories Ltd., #92 MOTION for Pro Hac Vice Appearance of Attorney Michael J. Gaertner, David B. Abramowitz, Carolyn A. Blessing and Emily L. Savas filed by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Limited. Signed by Judge Leonard P. Stark on 8/15/18. (ntl)
|
| Pro Hac Vice Attorney Emily L. Savas for Zydus Pharmaceuticals (USA) Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (dmp, ) |
| Filing 91 Joint STIPULATION Extend Time To Respond to the Complaint to September 12, 2018 for Defendants HEC Pharm Co., Ltd., HEC Pharm Group and HEC Pharm USA Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 90 MOTION for Pro Hac Vice Appearance of Attorney Stephen R. Auten, Attorney Richard T. Ruzich, Attorney Jaimin H. Shah and Attorney Roshan P. Shrestha - filed by Alkem Laboratories Ltd.. (Dorsney, Kenneth) |
| Filing 89 Joint STIPULATION and [Proposed] Order Dismissing Without Prejudice Defendant Intas Pharmaceuticals Ltd. and Amending Caption to Reflect Same by Accord Healthcare Inc., Intas Pharmaceuticals Limited. (Belgam, Neal) |
|
SO ORDERED, re #88 MOTION for Pro Hac Vice Appearance of Attorney Aaron F. Barkoff and Alejandro Menchaca filed by Ezra Ventures, LLC. Signed by Judge Leonard P. Stark on 8/14/18. (ntl)
|
| Filing 88 MOTION for Pro Hac Vice Appearance of Attorney Aaron F. Barkoff and Alejandro Menchaca - filed by Ezra Ventures, LLC. (Stamoulis, Stamatios) |
| Filing 87 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Pensa Pharma S.A. for Breckenridge Pharmaceutical, Inc. filed by Breckenridge Pharmaceutical, Inc.. (Farnan, Kelly) |
| Filing 86 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Standard Chemical & Pharmaceutical Co., Ltd.. (Farnan, Kelly) |
| Filing 85 ANSWER to #1 Complaint,,,,, Affirmative Defenses, COUNTERCLAIM against All Plaintiffs by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd..(Farnan, Kelly) |
|
Filing 84
ORAL ORDER: IT IS HEREBY ORDERED that the parties shall confer regarding proposed dates in the scheduling order and shall submit a proposal, including a proposal for the length and timing of trial, to the Court no later than August 27, 2018. The parties are to review the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Stark, New Patent Procedures). ORDERED by Judge Leonard P. Stark on 8/10/18. (ntl)
|
| Filing 83 DECLARATION of Mailing regarding service on Emcure Pharmaceuticals made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 82 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Nostrum Laboratories Inc., Nostrum Pharmaceuticals, LLC. (Finger, David) |
| Filing 81 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent MSN Laboratories Private Limited for MSN Laboratories Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmaceuticals Inc. filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc.. (Finger, David) |
| Filing 80 ANSWER to #1 Complaint,,,,, for Declaratory Judgment, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Nostrum Pharmaceuticals, LLC, MSN Laboratories Private Limited, Nostrum Laboratories Inc., MSN Pharmaceuticals Inc..(Finger, David) |
| Filing 79 NOTICE of Appearance by Megan C. Haney on behalf of Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc. (Haney, Megan) |
| Filing 78 NOTICE of Appearance by Megan C. Haney on behalf of Biocon Limited, Biocon Pharma, Inc. (Haney, Megan) |
|
SO ORDERED, re #76 MOTION for Pro Hac Vice Appearance of Attorney David H. Silverstein, Aziz Burgy, and Ricardo S. Camposanto filed by Par Pharmaceutical Inc., #68 MOTION for Pro Hac Vice Appearance of Attorney Howard S. Suh filed by Hetero Labs Limited Unit-V, Bionpharma Inc., Hetero USA Inc., Hetero Labs Limited, Prinston Pharmaceutical Inc. Signed by Judge Leonard P. Stark on 8/10/18. (ntl)
|
|
SO ORDERED, re #30 Stipulation filed by Novartis Pharmaceuticals Corporation, #72 Stipulation filed by Novartis Pharmaceuticals Corporation, #31 STIPULATION TO EXTEND TIME to respond to the Complaint to September 7, 2018 filed by Mylan Pharmaceuticals, Inc., #45 STIPULATION TO EXTEND TIME re Answer to Complaint to through and including August 13, 2018 filed by Standard Chemical & Pharmaceutical Co., Ltd., Breckenridge Pharmaceutical, Inc. Signed by Judge Leonard P. Stark on 8/10/18. (ntl)
|
| Pro Hac Vice Attorney Ricardo S. Camposanto,Aziz Burgy,David H. Silverstein for Par Pharmaceutical Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) |
| Filing 77 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Endo International PLC for Par Pharmaceutical Inc. filed by Par Pharmaceutical Inc.. (Cragg, Tyler) |
| Filing 76 MOTION for Pro Hac Vice Appearance of Attorney David H. Silverstein, Aziz Burgy, and Ricardo S. Camposanto - filed by Par Pharmaceutical Inc.. (Cragg, Tyler) |
| Filing 75 ANSWER to #1 Complaint,,,,, and Defenses by Par Pharmaceutical Inc..(Cragg, Tyler) |
| Filing 74 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent No parent company for Cadila Healthcare Limited filed by Cadila Healthcare Limited. (Phillips, John) |
| Filing 73 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Cadila Healthcare Limited for Zydus Pharmaceuticals (USA) Inc. filed by Zydus Pharmaceuticals (USA) Inc.. (Phillips, John) |
| Filing 72 STIPULATION and [Proposed] Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Filing 71 ANSWER to #1 Complaint,,,,, and Affirmative Defenses by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Phillips, John) |
| Filing 70 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma Limited for Aurobindo Pharma USA, Inc. filed by Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth) |
| Filing 69 ANSWER to #1 Complaint,,,,, , COUNTERCLAIM against All Plaintiffs by Aurobindo Pharma USA, Inc., Aurobindo Pharma Limited.(Dorsney, Kenneth) |
| Filing 68 MOTION for Pro Hac Vice Appearance of Attorney Howard S. Suh - filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc.. (Dorsney, Kenneth) |
| Filing 67 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Hetero Drugs Limited, Corporate Parent Hetero Labs Limited for Hetero USA Inc. filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Dorsney, Kenneth) |
| Filing 66 ANSWER to #1 Complaint,,,,, , COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Hetero USA Inc., Hetero Labs Limited Unit-V, Hetero Labs Limited.(Dorsney, Kenneth) |
| Filing 65 DECLARATION of Mailing regarding service on MSN Laboratories Private Limited made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 64 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent No parent company for Biocon Limited; Corporate Parent Biocon Limited for Biocon Pharma, Inc. filed by Biocon Limited, Biocon Pharma, Inc.. (Phillips, John) |
| Filing 63 DECLARATION of Mailing regarding service on Nostrum Laboratories Inc., USA made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 62 ANSWER to #1 Complaint,,,,, Affirmative Defenses and, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Biocon Limited, Biocon Pharma, Inc..(Phillips, John) |
| Filing 61 DECLARATION of Mailing regarding service on Hetero Labs Limited made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 60 DECLARATION of Mailing regarding service on Hetero Labs Limited Unit-V made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 59 DECLARATION of Mailing regarding service on HEC Pharm USA Inc. made on July 23, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 58 DECLARATION of Mailing regarding service on HEC Pharm Group made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 57 DECLARATION of Mailing regarding service on HEC Pharm Co., Ltd. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 56 DECLARATION of Mailing regarding service on Glenmark Pharmaceuticals Limited made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 55 DECLARATION of Mailing regarding service on Glenmark Pharmaceuticals Inc., USA made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 54 DECLARATION of Mailing regarding service on Ezra Ventures, LLC made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 53 DECLARATION of Mailing regarding service on Dr. Reddy's Laboratories, Ltd. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 52 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Torrent Private Ltd. for Torrent Pharmaceuticals Ltd.; Corporate Parent Torrent Pharmaceuticals Ltd. for Torrent Pharma Inc. filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Belgam, Neal) |
| Filing 51 DECLARATION of Mailing regarding service on Dr, Reddy's Laboratories, Inc. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 50 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Dr. Reddys Laboratories, Ltd. for Dr. Reddys Laboratories, Inc. filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd.. (Belgam, Neal) |
| Filing 49 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Intas Pharmaceuticals Limited for Accord Healthcare Inc. filed by Accord Healthcare Inc.. (Belgam, Neal) |
| Filing 48 ANSWER to #1 Complaint,,,,, and Additional Defenses by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Filing 47 ANSWER to #1 Complaint,,,,, and Additional Defenses by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Filing 46 ANSWER to #1 Complaint,,,,, and Additional Defenses by Accord Healthcare Inc..(Ormerod, Eve) |
| Filing 45 STIPULATION TO EXTEND TIME re Answer to Complaint to through and including August 13, 2018 - filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd.. (Farnan, Kelly) |
| Filing 44 DECLARATION of Mailing regarding service on Standard Chemical & Pharmaceutical Co., Ltd. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 43 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Ezra Innovations LLC for Ezra Ventures, LLC filed by Ezra Ventures, LLC. (Stamoulis, Stamatios) |
| Filing 42 DECLARATION of Mailing regarding service on Breckenridge Pharmaceutical, Inc. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 41 ANSWER to #1 Complaint,,,,, , COUNTERCLAIM against All Plaintiffs by Ezra Ventures, LLC.(Stamoulis, Stamatios) |
| Filing 40 DECLARATION of Mailing regarding service on Biocon Limited made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 39 DECLARATION of Mailing regarding service on Aurobindo Pharma Limited made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 38 DECLARATION of Mailing regarding service on Alkem Laboratories, Ltd. made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 37 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Bionpharma Inc.. (Dorsney, Kenneth) |
| Filing 36 DECLARATION of Mailing regarding service on Accord Healthcare Inc. made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 35 ANSWER to #1 Complaint,,,,, , COUNTERCLAIM against All Plaintiffs by Bionpharma Inc..(Dorsney, Kenneth) |
| Filing 34 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Zhejiang Huahai Pharmaceutical Co., Ltd. for Prinston Pharmaceutical Inc. filed by Prinston Pharmaceutical Inc.. (Dorsney, Kenneth) |
| Filing 33 ANSWER to #1 Complaint,,,,, for Patent Infringement, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Filing 32 NOTICE of Appearance by Frederick L. Cottrell, III on behalf of Mylan Pharmaceuticals, Inc. (Cottrell, Frederick) |
| Filing 31 STIPULATION TO EXTEND TIME to respond to the Complaint to September 7, 2018 - filed by Mylan Pharmaceuticals, Inc.. (Rawnsley, Jason) |
| Filing 30 STIPULATION and [Proposed] Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
|
SO ORDERED, re #29 STIPULATION TO EXTEND TIME to ANSWER complaint to September 7, 2018 filed by Strides Global Pharma Private Limited, Strides Pharma, Inc. Signed by Judge Leonard P. Stark on 8/8/18. (ntl)
|
|
SO ORDERED, re #25 STIPULATION TO EXTEND TIME Respond to Complaint to September 17, 2018 filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 8/8/18. (ntl)
|
|
SO ORDERED, re #26 Stipulation of Dismissal filed by Alkem Laboratories Ltd. -- Party S&B Pharma, Inc. terminated. Signed by Judge Leonard P. Stark on 8/8/18. (ntl)
|
|
SO ORDERED, re #19 Stipulation and Order filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 8/8/18. (ntl)
|
| CORRECTING ENTRY: Stipulation filed at D.I. 27 was removed from the docket as duplicative of D.I. 26. (ntl) |
| Pro Hac Vice Attorney Robert W. Trenchard for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:18-cv-01038-LPS, 1:18-cv-01039-LPS, 1:18-cv-01040-LPS, 1:18-cv-01043-LPS(ceg) |
| Filing 29 STIPULATION TO EXTEND TIME to ANSWER complaint to September 7, 2018 - filed by Strides Global Pharma Private Limited, Strides Pharma, Inc.. (Rychlicki, Helena) |
| Filing 28 NOTICE of Appearance by Helena C. Rychlicki on behalf of Strides Global Pharma Private Limited, Strides Pharma, Inc. (Rychlicki, Helena) |
| Filing 26 STIPULATION of Dismissal of S&B Pharma, Inc. without prejudice and Amending Caption by Alkem Laboratories Ltd.. (Dorsney, Kenneth) |
| Filing 25 STIPULATION TO EXTEND TIME Respond to Complaint to September 17, 2018 - filed by Alkem Laboratories Ltd.. (Dorsney, Kenneth) |
| Filing 24 DECLARATION of Mailing regarding Service on Torrent Pharmaceuticals Ltd. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 23 DECLARATION of Mailing regarding Service on Torrent Pharma Inc. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 22 DECLARATION of Mailing regarding service on Strides Pharma, Inc. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 21 DECLARATION of Mailing regarding service on Strides Global Pharma Private Limited made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 20 DECLARATION of Mailing Regarding Service on Defendant Zydus Pharmaceuticals (USA) Inc. made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B)(Silver, Daniel) |
| Filing 19 STIPULATION and [Proposed] Order as to Defendant First Time US Generics LLC by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Pro Hac Vice Attorney Jane M. Love for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:18-cv-01038-LPS, 1:18-cv-01039-LPS, 1:18-cv-01040-LPS, 1:18-cv-01043-LPS(dmp, ) |
| Pro Hac Vice Attorney Andrew Blythe for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:18-cv-01038-LPS, 1:18-cv-01039-LPS, 1:18-cv-01040-LPS, 1:18-cv-01043-LPS(dmp, ) |
| Filing 18 SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Bionpharma Inc. served on 7/18/2018, answer due 8/8/2018. (Silver, Daniel) |
| Filing 17 SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Nostrum Pharmaceuticals, LLC served on 7/18/2018, answer due 8/8/2018. (Silver, Daniel) |
| Filing 16 SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Mylan Pharmaceuticals, Inc. served on 7/18/2018, answer due 8/8/2018. (Silver, Daniel) |
| Filing 15 SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Prinston Pharmaceutical Inc. served on 7/18/2018, answer due 8/8/2018. (Silver, Daniel) |
| Filing 14 SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. S&B Pharma, Inc. served on 7/18/2018, answer due 8/8/2018. (Silver, Daniel) |
| Filing 13 SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. MSN Pharmaceuticals Inc. served on 7/18/2018, answer due 8/8/2018. (Silver, Daniel) |
| Filing 12 SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Hetero USA Inc. served on 7/19/2018, answer due 8/9/2018. (Silver, Daniel) |
| Filing 11 SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Par Pharmaceutical Inc. served on 7/19/2018, answer due 8/9/2018. (Silver, Daniel) |
| Filing 10 SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Heritage Pharmaceuticals Inc. served on 7/19/2018, answer due 8/9/2018. (Silver, Daniel) |
| Filing 9 SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Aurobindo Pharma USA, Inc. served on 7/19/2018, answer due 8/9/2018. (Silver, Daniel) |
| Filing 8 SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. First Time US Generics LLC served on 7/18/2018, answer due 8/8/2018. (Silver, Daniel) |
| Filing 7 SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Biocon Pharma, Inc. served on 7/19/2018, answer due 8/9/2018. (Silver, Daniel) |
|
SO ORDERED, re (6 in 1:18-cv-01039-LPS, 6 in 1:18-cv-01038-LPS, 6 in 1:18-cv-01043-LPS, 6 in 1:18-cv-01040-LPS) MOTION for Pro Hac Vice Appearance of Attorney Jane M. Love, Robert Trenchard, Paul E. Torchia, and Andrew P. Blythe filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 7/24/18. Associated Cases: 1:18-cv-01038-LPS, 1:18-cv-01039-LPS, 1:18-cv-01040-LPS, 1:18-cv-01043-LPS (ntl)
|
| Filing 6 MOTION for Pro Hac Vice Appearance of Attorney Jane M. Love, Robert Trenchard, Paul E. Torchia, and Andrew P. Blythe - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Certifications for Jane M. Love, Robert Trenchard, Paul E. Torchia, and Andrew P. Blythe)(Silver, Daniel) |
| Summons Reissued with Magistrate Consent Notice attached as to HEC Pharm USA Inc. (jcs) |
| Summons Reissued with Magistrate Consent Notice attached as to Accord Healthcare Inc., HEC Pharm Group, Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Par Pharmaceutical Inc., Zydus Pharmaceuticals (USA) Inc.. (nmg) |
| Summons Reissued with Magistrate Consent Notice attached as to Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc. (nmg) |
| Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:18-cv-01038-LPS, 1:18-cv-01039-LPS, 1:18-cv-01040-LPS, 1:18-cv-01043-LPS (rjb) |
| Summons Issued with Magistrate Consent Notice attached as to Accord Healthcare Inc. on 7/18/2018; Alkem Laboratories Ltd. on 7/18/2018; Aurobindo Pharma Limited on 7/18/2018; Aurobindo Pharma USA, Inc. on 7/18/2018; Biocon Limited on 7/18/2018; Biocon Pharma, Inc. on 7/18/2018; Bionpharma Inc. on 7/18/2018; Breckenridge Pharmaceutical, Inc. on 7/18/2018; Cadila Healthcare Limited on 7/18/2018; Dr. Reddys Laboratories, Inc. on 7/18/2018; Dr. Reddys Laboratories, Ltd. on 7/18/2018; Emcure Pharmaceuticals on 7/18/2018; Ezra Ventures, LLC on 7/18/2018; First Time US Generics LLC on 7/18/2018; Glenmark Pharmaceuticals Inc., USA on 7/18/2018; Glenmark Pharmaceuticals Limited on 7/18/2018; HEC Pharm Co., Ltd. on 7/18/2018; HEC Pharm Group on 7/18/2018; HEC Pharm USA Inc. on 7/18/2018; Heritage Pharmaceuticals Inc. on 7/18/2018; Hetero Labs Limited on 7/18/2018; Hetero Labs Limited Unit-V on 7/18/2018; Hetero USA Inc. on 7/18/2018; Intas Pharmaceuticals Limited on 7/18/2018; MSN Laboratories Private Limited on 7/18/2018; MSN Pharmaceuticals Inc. on 7/18/2018; Mylan Pharmaceuticals, Inc. on 7/18/2018; Nostrum Laboratories Inc. on 7/18/2018; Nostrum Pharmaceuticals, LLC on 7/18/2018; Par Pharmaceutical Inc. on 7/18/2018; Prinston Pharmaceutical Inc. on 7/18/2018; S&B Pharma, Inc. on 7/18/2018; Standard Chemical & Pharmaceutical Co., Ltd. on 7/18/2018; Strides Global Pharma Private Limited on 7/18/2018; Strides Pharma, Inc. on 7/18/2018; Torrent Pharma Inc. on 7/18/2018; Torrent Pharmaceuticals Ltd. on 7/18/2018; Zydus Pharmaceuticals (USA) Inc. on 7/18/2018. (sar) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (nmg) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,187,405. (nmg) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: See Attached. Date of Expiration of Patent: 6/25/2027. (nmg) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) |
| Filing 1 COMPLAINT for PATENT INFRINGEMENT filed against Accord Healthcare Inc., Alkem Laboratories Ltd., Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Biocon Limited, Biocon Pharma, Inc., Bionpharma Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Emcure Pharmaceuticals, Ezra Ventures, LLC, First Time US Generics LLC, Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited, HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc., Heritage Pharmaceuticals Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Intas Pharmaceuticals Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., Mylan Pharmaceuticals, Inc., Nostrum Laboratories Inc., Nostrum Pharmaceuticals, LLC, Par Pharmaceutical Inc., Prinston Pharmaceutical Inc., S&B Pharma, Inc., Standard Chemical & Pharmaceutical Co., Ltd., Strides Global Pharma Private Limited, Strides Pharma, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Zydus Pharmaceuticals (USA) Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2420075.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibit A-B, #2 Civil Cover Sheet)(nmg) |
| No Summons Issued. (nmg) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
